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Abstract
I develop new statistical methods to learn the fraction who benefit from treat-
ment, using randomized trial data. Defined in the potential outcomes framework,
the fraction who benefit is the proportion of patients whose potential outcome under
treatment is better than that under control. Since only one potential outcome can
be observed for any given person, this fraction is a non-identifiable parameter unless
strong assumptions are made about the joint probability distribution of the potential
outcomes. A strength of my methods is that they do not require assumptions about
the joint distribution, but can incorporate a wide range of user-defined assumptions
based on subject matter knowledge. I derive sharp lower and upper bounds on the
fraction and develop a method to estimate these bounds, which is consistent and
computationally efficient. The method is illustrated through an application to the
MISTIE II (Minimally Invasive Surgery for Intracerebral Hemorrhage Evacuation
Phase II) randomized trial on intracerebral hemorrhage. In addition, I develop a
method to construct a confidence interval for the fraction who benefit, and prove
that it is pointwise consistent. The method is demonstrated through an application
ii
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to the CLEAR III (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular
Haemorrhage III) randomized trial on intraventricular hemorrhage.
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In many randomized controlled trials, the primary analysis focuses on the average
treatment effect and does not address whether treatment benefits are widespread
or limited to a select few. This problem affects many disease areas, since it stems
from how randomized trials, often the gold standard for evaluating treatments, are
designed and analyzed. My aim is to make inferences about the fraction who benefit
from treatment, using randomized trial data. This fraction is formally defined as the
proportion of patients whose potential outcome under treatment is better than that
under control. In other words, it is the fraction who are better off with treatment. The
fraction who benefit is of interest to patients and doctors selecting between treatment
and control. In addition, it can be a useful tool for medical researchers. For example,
if the fraction is small, this is a signal to researchers that they should devote resources
toward identifying the exclusive subgroup that benefits from treatment.
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Since we can observe only one potential outcome per person (Holland, 1986),
the fraction who benefit is typically non-identifiable without strong, untestable as-
sumptions about the joint distribution of the potential outcomes. Examples of such
assumptions include independence of the potential outcomes, or conditional indepen-
dence of the potential outcomes given baseline covariates collected in the trial (Zhang
et al., 2013). To maximize the applicability of my methods, I avoid requiring strong
assumptions. The two methods proposed in Chapters 2 and 3 of this thesis do not
require any assumptions about the joint distribution of the potential outcomes. How-
ever, they allow the user to incorporate certain assumptions based on subject matter
knowledge. The user-defined assumptions that can be incorporated are restrictions
on the support of the joint distribution of the potential outcomes. One example is
the no harm assumption, which is that for any given person the potential outcome
under treatment is no worse than the potential outcome under control.
In Chapter 2, I derive and estimate sharp lower and upper bounds on the fraction
who benefit. The main contributions in this chapter include (i) deriving bound pa-
rameters that are identifiable, (ii) proving the plug-in estimator can be inconsistent if
support restrictions are made on the joint distribution of the potential outcomes; (iii)
developing the first consistent estimator for this case; (iv) applying this estimator to
the MISTIE II (Minimally Invasive Surgery for Intracerebral Hemorrhage Evacuation
Phase II) randomized trial to determine whether the estimates can be informative.
The proposed estimator is computed using linear programming, which has readily
2
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available software that is efficient. The bound estimates can typically be computed
in under a second.
In Chapter 3, I address the question of how to construct a confidence interval
for the fraction who benefit. The main contributions in this chapter include (i)
developing a new method to construct a confidence interval for the fraction using
randomized trial data, (ii) proving the confidence interval is pointwise consistent, (iii)
evaluating its empirical coverage and width at finite sample sizes through simulation,
(iv) applying it to the CLEAR III (Clot Lysis: Evaluating Accelerated Resolution
of Intraventricular Haemorrhage III) randomized trial to compare alteplase versus
saline in treating patients with severe stroke. In simulation, the proposed method
can have substantially smaller average width compared to an existing method using
the m-out-of-n bootstrap on the bounds. Also, the new method is computationally
efficient because it utilizes quadratic programming.
The methods in Chapters 2 and 3 are designed for an ordinal outcome, with binary
outcomes as a special case. In Chapter 4, I recapitulate the main contributions of my
thesis work and discuss future directions.
Excerpts of this chapter and Chapter 2 are from the paper entitled “Inequality in Treatment
Benefits: Can We Determine if a New Treatment Benefits the Many or the Few?”, which has been
published in Biostatistics (Huang et al., 2017).
3
Chapter 2
Estimating Bounds on the Fraction
who Benefit using Randomized Trial
Data
2.1 Introduction
We aim to estimate bounds on the fraction of the population who benefit from
a treatment. This fraction is defined in the potential outcomes framework. Each
participant has two potential outcomes, one representing the participant’s outcome if
assigned to treatment and the other if assigned to control. The fraction who benefit
is defined as the fraction of the population whose potential outcome under treatment
is better than that under control. In other words, it is the fraction who would be
4
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better off under treatment. Without strong assumptions, the fraction who benefit is
generally a non-identifiable parameter. This is because only one potential outcome
can be observed for any given individual (Holland, 1986). However, sharp bounds
on the fraction are identifiable (Williamson and Downs, 1990; Manski, 1997; Fan and
Park, 2009, 2010; Kim, 2014).
We derive bounds using the marginal distributions of the potential outcomes, and
show these bounds can be narrowed using a prognostic baseline variable and/or user-
defined assumptions. The type of user-defined assumptions considered are restrictions
on the support of the joint distribution of the potential outcomes, e.g., the no harm
assumption. Our main contributions include (i) proving the plug-in estimator of
the bounds can be inconsistent if support restrictions are made; (ii) developing the
first consistent estimator for this case; (iii) applying this estimator to a randomized
trial data set of a medical treatment to determine whether the estimates can be
informative. We assume a simple randomized trial design, i.e., each participant’s
treatment assignment is an independent draw from a Bernoulli distribution. Our
estimator can be computed using linear programming, i.e., the optimization of a linear
objective function subject to linear equality and inequality constraints (Vanderbei,
2013). The bound estimates are typically computed in under a second.
We apply our estimator to the MISTIE II (Minimally Invasive Surgery for In-
tracerebral Hemorrhage Evacuation Phase II) randomized trial (Morgan et al., 2008;
Hanley et al., 2016), which compared a new surgical intervention for stroke to stan-
5
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dard medical management. As an example of our results in one case, the lower and
upper bound estimates on the fraction who benefit are 0.10 and 0.73 when the out-
come is a rating of functional disability 180 days post-stroke, and 0.82 and 0.96 when
the outcome is reduction in clot volume.
Related work includes Manski (1997); Gadbury et al. (2004); Fan and Park (2009,
2010); Zhang et al. (2013); Kim (2014); Borusyak (2015). Fan and Park (2009, 2010)
prove sharp bounds on the fraction who benefit, given the marginal distributions of
the potential outcomes. Kim (2014) tightens those bounds using support restrictions
on the joint distribution. Both propose estimators for their respective bounds. A key
difference of our work, compared to Fan and Park (2009, 2010) and Kim (2014), is
that we handle an ordinal outcome, while they handle a continuous outcome. Apply-
ing their formulae to an ordinal outcome can yield erroneous results (Section 2.3.1).
Unlike Fan and Park (2009, 2010), we allow the incorporation of support restrictions,
which leads to a more challenging estimation problem. We propose a new estimator
that can be computed efficiently using linear programming. In contrast, the estimator
of Kim (2014) generally requires solving a non-convex optimization problem to incor-
porate support restrictions. Non-convex problems are much more computationally
difficult than linear programs.
Gadbury et al. (2004) derive bounds on the fraction who are harmed, given the
marginal distributions of the potential outcomes, when the outcome is binary and
no baseline variable/support restrictions are used (see Section 2.3.1); in contrast, we
6
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consider ordinal outcomes, baseline variables, and support restrictions. For an ordinal
outcome, Borusyak (2015) shows that sharp bounds on the fraction who benefit can
be computed with linear programming. Borusyak does not address estimation of
these bounds, which is a focus of our work.
Manski (1997) derives sharp bounds on the fraction who benefit given the no harm
assumption, without using the marginal distributions of the potential outcomes. We
can incorporate the no harm assumption but do not require it. We use the marginal
distributions since they are identifiable in the randomized trial context. The method
by Manski is designed for settings where treatment assignment is not random. Zhang
et al. (2013) estimate the fraction who benefit, rather than bounds on it, by assuming
the potential outcomes are conditionally independent given a set of baseline covariates
collected in the trial.
The structure of this chapter is as follows. The MISTIE II trial is introduced in
Section 2.2. The bound parameters are defined in Section 2.3. In Section 2.4, we
prove that the plug-in estimator can be inconsistent, propose a new estimator that is
consistent and computationally efficient, and discuss inference based on this estimator
(which is challenging due to potential non-regularity). We apply our estimator to
MISTIE II in Section 2.5, and present simulation results in Section 2.6. Future
directions are discussed in Section 2.7.
7
CHAPTER 2. ESTIMATING BOUNDS ON THE FRACTION WHO BENEFIT
2.2 MISTIE II Trial
MISTIE II is a recently completed Phase II randomized trial for intracerebral
hemorrhage (ICH), a type of stroke that can impair cognitive/motor functions and
cause death (Morgan et al., 2008; Hanley et al., 2016). The MISTIE II trial assessed
the effectiveness of image-guided minimally invasive surgery (i.e., treatment), relative
to standard medical care (i.e., control). There were 96 participants, with 54 assigned
to treatment and 42 to control. The randomization ratio gave a higher likelihood of
being assigned to treatment, yielding the higher proportion of treatment participants.
The primary outcome was a rating of functional disability at 180 days post-stroke,
measured by the modified Rankin Scale (mRS) (Quinn et al., 2009). The mRS score
is ordinal, defined as an integer between 0 (no symptoms) and 6 (death), with lower
scores corresponding to improved functioning (Cheng et al., 2014). In the primary
analysis comparing treatment to control, the average treatment effect (ATE) was
inferred, i.e., the difference in population proportions with 180-day mRS  3. The
estimate of ATE was 0.11 (95% CI: [-0.09, 0.29]), using the 52 treatment and 38
control participants with recorded 180-day mRS scores. Patients and doctors may
also be interested in the fraction who benefit, i.e., the fraction of patients who would
have a better 180-day mRS under treatment than under control. Since it divides
mRS into two categories ( 3 or > 3), the ATE misses benefits within a category. In
general, the population ATE is not designed to be informative about the fraction. If
the outcome is ordinal, the ATE (e.g., the mean difference in the outcome between
8
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treatment and control) can be large, while the fraction is small; this could occur if






as the potential outcomes under control and treatment, re-
spectively. Suppose the outcome is ordinal with L levels, i.e., 1, 2, .., L, ordered from
least to most favorable. For MISTIE, we recode mRS score in this way with L = 7,
setting 1 to represent death, and 7 to represent no symptoms. This definition of mRS
score will be used throughout this chapter. Let X be a prognostic baseline variable
collected in the randomized trial. For each participant, define the vector including




). We let P




) and P0 denote the true (unknown)




). We assume that each participant’s vector V is an in-
dependent, identically distributed draw from P0. For each participant, the observed
data is (X,A, Y ), where A is the random treatment assignment (1 if treatment, 0 if
control) which is independent of V , and Y is the observed outcome corresponding to










), despite never observing the full pair of potential outcomes for any participant.
Although the fraction  is generally non-identifiable, certain possibilities can be ruled
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. The bounds can be improved by incorporating X or assumptions about
P , as discussed in Section 2.3.2.
2.3.1 Sharp bounds on the fraction who benefit based
on FC and FT
Let ⇡
i,j











= j). Let L be the set of integers from 1 to L. The ⇡
i,j
’s (i, j 2 L) form an L
x L matrix giving the joint distribution of the potential outcomes (JDPO), depicted




, respectively, as shown in the figure. For example, the sum of the ⇡
i,j
’s in the
fourth column equals p
T
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): those for whom assignment to treatment (compared to control) would













correspond to the yellow, red, and green regions in Figure 2.1, respectively. The pa-
rameter  is the fraction of the population in the green region, i.e., the sum of ⇡
i,j
over indices (i, j) with j > i. The value of  , in general, is non-identifiable since for
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The upper bound  
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is (2.1) with inf replaced by sup, and (2.2) with min replaced
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are solutions to linear programs (Borusyak, 2015). The objective function is linear
because it is the sum of the ⇡
i,j
’s in the green region. The constraints are all linear
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y2R{FC(y)   FT (y)} and 1   supy2R{FT (y)   FC(y)}, respectively




y2R{FC(y)  FT (y)}, while the upper bound  u can be different
from 1  sup
y2R{FT (y)  FC(y)}.
Example (Case where  u 6= 1   supy2R{FT (y)   FC(y)}) Consider the case of
a binary outcome (L = 2) with possible values 1 = failure and 2 = success. Assume




























2.3.2 General formulation of sharp bounds on the
fraction who benefit
We generalize the bound formulation to incorporate a baseline variable and sup-
port restrictions. Since they offer new information, these features can narrow the
bounds (Fan and Park, 2010; Kim, 2014). We consider a baseline, i.e., pre-randomization,
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variable that is categorical and conjectured to be prognostic for (i.e., correlated with)
the outcome. Suppose the baseline variable X has K < 1 possible values: x1, .., xK .
Let p
X




) = P (X = x
k
) > 0 for each k.













In addition to a baseline variable, support restrictions are another feature that can




= j) = 0
for specific (i, j) pairs. They are encoded by a function g : L⇥L ! {0, 1} that maps




) = (i, j) to 0 if the pair is assumed not possible,
and 1 otherwise. Equivalently, g(i, j) = 0 encodes the assumption that ⇡
i,j
= 0. The
support restrictions in our application (Section 2.5) are restrictions on harm/benefit.
The restriction Harm  d levels is: ⇡
i,j
= 0 if i  j > d. The no harm assumption is
the special case with d = 0. The restriction Benefit  d levels is: ⇡
i,j
= 0 if j  i > d.
Figure 2.2 illustrates Benefit  3 levels for MISTIE. We refer to support restrictions
simply as restrictions.
We assume the restrictions, i.e., the function g, are prespecified and known. Let









= j) = 0 if g(i, j) = 0.
Assumption 1 The true joint distribution P0(X, YC , YT ) is consistent with R, i.e.,
the distribution P0(YC , YT ), which is formed by marginalizing P0(X, YC , YT ) over X,
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Y
T
1 2 3 4 5 6 7
Y
C
1 ⇡1,1 ⇡1,2 ⇡1,3 ⇡1,4 ⇡1,5 ⇡1,6 ⇡1,7 pC(1)
2 ⇡2,1 ⇡2,2 ⇡2,3 ⇡2,4 ⇡2,5 ⇡2,6 ⇡2,7 pC(2)
3 ⇡3,1 ⇡3,2 ⇡3,3 ⇡3,4 ⇡3,5 ⇡3,6 ⇡3,7 pC(3)
4 ⇡4,1 ⇡4,2 ⇡4,3 ⇡4,4 ⇡4,5 ⇡4,6 ⇡4,7 pC(4)
5 ⇡5,1 ⇡5,2 ⇡5,3 ⇡5,4 ⇡5,5 ⇡5,6 ⇡5,7 pC(5)
6 ⇡6,1 ⇡6,2 ⇡6,3 ⇡6,4 ⇡6,5 ⇡6,6 ⇡6,7 pC(6)
















Figure 2.1: Joint Distribution of the Potential Outcomes.
Y
T
1 2 3 4 5 6 7
Y
C
1 ⇡1,1 ⇡1,2 ⇡1,3 ⇡1,4 0 0 0 pC(1)
2 ⇡2,1 ⇡2,2 ⇡2,3 ⇡2,4 ⇡2,5 0 0 pC(2)
3 ⇡3,1 ⇡3,2 ⇡3,3 ⇡3,4 ⇡3,5 ⇡3,6 0 pC(3)
4 ⇡4,1 ⇡4,2 ⇡4,3 ⇡4,4 ⇡4,5 ⇡4,6 ⇡4,7 pC(4)
5 ⇡5,1 ⇡5,2 ⇡5,3 ⇡5,4 ⇡5,5 ⇡5,6 ⇡5,7 pC(5)
6 ⇡6,1 ⇡6,2 ⇡6,3 ⇡6,4 ⇡6,5 ⇡6,6 ⇡6,7 pC(6)
















Figure 2.2: Support Restriction: Benefit  3 levels.
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denote the sharp lower and upper bounds on  , respectively,
given the baseline variable X and restrictions R. These bounds are functions of R and




) in a randomized trial where study arm is













































k=1, pX) is (2.4), with sup in place of inf.
Let  R
l
denote the lower bound with restrictions R but ignoring the baseline





k=1, pX replaced by FC , FT . Let  Xl denote
the lower bound with the baseline variable but no restrictions R, i.e., (2.3)-(2.4) with






















is a function of the joint














k=1, pX of P ;
the bound  
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We suppress the dependence of these parameters on P for conciseness.
Incorporating a baseline variable or restriction leads to a larger or equal lower
bound, and smaller or equal upper bound.
Theorem 1 Consider any restrictions R, baseline variable X, and joint distribu-















}    
l










}   
u
, where each











, and X, respec-









given X = x
k





























































































































































k=1, pX , and R. Inequalities (2.6) and (2.10) hold because the constraint
that P 0 is consistent with R has been removed on the right sides, so the inf is being
taken over an increased set leading to a smaller or equal value. Inequalities (2.8) and
(2.12) hold because the inf is being taken over an increased set on the right sides, since





k=1, pX is also consistent with FC , FT , as shown
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below:





k=1, pX (which are the marginal distributions









 y|X = x
k




















 y|X = x
k









so P 0 is consistent with F
C






























}    
l
. The results for the upper bound parameters
can be proved analogously. ⇤
Just as in Fan and Park (2010), the baseline variable X will not affect the bounds if




). This claim is justified at the end of this section.












) that is consistent





k=1, pX . In this case, the bound parameter (2.4) is undefined,
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since the set of distributions on the right hand side is empty. This cannot occur if
the distribution P is consistent with R. However, the user may impose restrictions
R that are in violation of Assumption 1. This can lead to the bound parameters
evaluated at P0, such as  R,X
l
(P0), being undefined.
Bounds on the fraction who benefit can be derived for a subpopulation. For any




denote the sharp lower and upper bounds for subpopula-





























































































0 = F k
T























































= j|X = x
k
) for each i, j. The upper bound  R,X
u,k
is (2.13) with sup in place of inf, and (2.14) with max in place of min. The population
lower bound is a weighted sum of the subpopulation lower bounds, where the weights
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equal the size of the subpopulation relative to the full population. Analogously, the
population upper bound is a weighted sum of the subpopulation upper bounds, with
the same weights.
Theorem 2 Consider any restriction R, baseline variable X, and joint distribution






























where each parameter is evaluated at P . This also holds with the restrictions R
omitted.















































(y) = P (Y
C
 y|X = x
k
) and F k
T
(y) = P (Y
T
 y|X = x
k





) = P (X = x
k




















































k=1 are solutions to linear programs, inf
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can be replaced with min, and sup with max in the four definitions above.














































) that (i) are con-


































). For any k, there



















) =  R,X
l,k






























) for each k. It follows that P
l













































) are in (2.15).





















minimum and maximum of (2.15), respectively. We do a proof by contradiction.




























) <  R,X
l,k
. However, this












) is the minimum of (2.15).
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The relationship also holds if the restrictions R are omitted. This can be proved
as above, with R corresponding to the indicator function g that maps all potential
outcome pairs to 1 (which is equivalent to no restrictions). ⇤
Theorem 2 is a useful result since it shows that, to incorporate a baseline variable,
one only needs to compute the bounds within subpopulation and take a weighted sum
of the subpopulation bounds. In Section 2.4, we also use this strategy to estimate the
bounds that incorporate a baseline variable. In other words, we compute the bound
estimate within each stratum and take the weighted sum of the bound estimates.





) does not result in any narrowing of the bounds. This claim follows from
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2.4 Bound Estimators
We discuss estimators for the bound parameters defined in Section 2.3, using data
from a randomized trial with n participants. We make the assumption below:









an independent, identically distributed draw from P0. (ii) The treatment assignments,
A
m
















Above, (ii) is justified by randomization and we assume the randomization probability
✓ : 0 < ✓ < 1. The equality in (iii) is called the consistency assumption, which




) and treatment assignment A to the observed
outcome Y .
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2.4.1 Plug-in estimator





























m=1 1(Ym  y, Am = 0, Xm = xk)
P
n







m=1 1(Ym  y, Am = 1, Xm = xk)
P
n
m=1 1(Am = 1, Xm = xk)
,









Above, 1(E) has value 1 if E occurs and 0 otherwise. We use the hat symbol to
denote plug-in estimators, e.g., b 
l
.
The plug-in estimator can be inconsistent when support restrictions are made,
even if they are correct. Consider the case where the outcome is binary, the baseline
variable is ignored, and the true, unknown joint distribution P0 on (YC , YT ) satisfies
P0(YC = YT ) = 1. Then the true marginals satisfy P0(YC = y) = P0(YT = y) for each





is assumed to have probability 0. The restrictions are consistent with P0. The bound





















are undefined. The probability P0( bFT (1) > bFC(1))
converges to 0.5 as n goes to infinity, as proved below.
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(1). Since ✓ = 12 and FC(1) = FT (1), we have
P0( bFT (1) > bFC(1)) = P0( bFT (1) < bFC(1)). Therefore,
P0( bFT (1) > bFC(1)) =
1  P0( bFT (1) = bFC(1))
2
.
Now let n go to infinity. Then we have
lim
n!1
P0( bFT (1) > bFC(1)) = lim
n!1












undefined with approximately 0.5 probability for arbitrarily large n.













could make them infea-




are like (2.2), except with the constraint
“⇡
i,j




are inconsistent if, for




given by (2.14) are feasible but an




can make them infeasible. We refer to these
cases as boundary cases. Boundary cases can only occur if restrictions are made.
They can occur when the true fraction who benefit and the bound parameters are
nonzero, as shown in the following example.
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Example Consider an ordinal outcome with three levels (1,2,3, ordered from worst






1 0.2 0.3 0 0.5
2 0 0.3 0 0.3
3 0 0 0.2 0.2
0.2 0.6 0.2
Therefore, the fraction who benefit  = P0(YT > YC) is 0.3.
Suppose that the no harm assumption is imposed, and thus R = {no harm}. The




) that satisfies the no harm assumption and has the









. These are the minimum and max-
imum fraction who benefit, among all matrices that satisfy the no harm assumption




. The structure of


















1 ⇡1,1 ⇡1,2 ⇡1,3 bpC(1)
2 0 ⇡2,2 ⇡2,3 bpC(2)












are undefined (i.e., there exist no















converges to 0 because p
T
(1) = 0.2 while p
C









(3) = 0.2. Thus, at




are undefined with probability












































For each k, the term  R,X
l,k
is computed by the following sequence of two linear
27































































































































































































































































The term  R,X
u,k
is (2.18), with min replaced by max. (2.17) and (2.18) are linear
programs because each absolute value statement can be converted to a pair of linear
inequalities.
The key idea in (2.18) is that we relaxed the constraint that the marginal dis-
tribution functions corresponding to ⇡k
i,j
equal the empirical marginal distribution
28
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functions in stratum k; we instead allow these to differ by at most ✏
k
. As defined in
(2.17), the value of ✏
k


























undefined, we have ✏
k









, are defined analogously. Their definitions are shown below. In the case where no
restrictions are made, our estimator is equivalent to the plug-in estimator.
With neither baseline variable nor restriction,  l and  u
The lower bound estimator  
l



























✏   0 :
⇡
i,j








































































































































The upper bound estimator  
u
is (2.20), with min replaced by max.
With restriction and ignoring baseline variable,  
R
l and  
R
u
The lower bound estimator  R
l






































✏   0 :
⇡
i,j






















j=1 ⇡i,j = 1
⇡
i,j












































































































j=1 ⇡i,j = 1
⇡
i,j






































The upper bound estimator  R
u
is (2.22), with min replaced by max.
With baseline variable and no restriction,  
X
l and  
X
u


































where the term  X
l,k


















































































































































































































The term  X
u,k
is (2.25), with min replaced by max.
2.4.3 Consistency of the Proposed Estimator




are consistent, i.e., they converge to
the corresponding bound parameters as n goes to infinity. By a similar proof, the
estimators that ignore baseline variables and/or have no restrictions are consistent.







consistent estimators of  R,X
l
(P0) and  R,X
u
(P0), respectively.
Proof In this proof, limits are taken as n ! 1. For example, p! signifies con-
vergence in probability as n ! 1. Define 1
E
to be a random variable which takes





[z1,j, z2,j, ..., zL,j] and [zi,j]L








where y = (y1, y2, .., yM)T .
Consider any X and R. Let P0 be any joint distribution on (X, YC , YT ) consistent
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(P0) as n ! 1. Below, we suppress the dependence of the bound





k=1, pX be the marginal distributions
corresponding to P0.




















for each k. By Slutsky’s Theorem,










. By the Weak Law of Large
Numbers, (I) follows from Assumption 2(i). We must show that (II) also holds.





. Fix n 2 N. Consider
the following linear program, which we refer to as LP:
min
x
cTx, subject to Ax  b, x   0.
































takes the value 1 if j > i and 0 otherwise. Define A as the matrix that
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When b = bn, LP is equivalent to the linear program for  
R,X
l,k




 1. When b = b⇤, LP is equivalent to the linear program for  R,X
l,k
. Therefore,
f(b⇤) =  R,X
l,k
 1. (LP is feasible when b = b⇤ since P0 is consistent with R.) By
Lemma 1 below, there exists a constant C > 0 such that |f(b)  f(b⇤)|  Ckb  b⇤k2
for any b with f(b) < 1. This means that |f(bn)  f(b⇤)|  Ckbn  b⇤k2. Choose any






| > ⌘) = P0(|f(bn)  f(b⇤)| > ⌘)
 P0
⇣
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By Lemma 2 below, ✏
k










(j) for all i, j =


























i, j = 1, .., L 1. By Theorem 11.9 in Severini (2005), lim
n!1 P0
 



















































Lemma 1 Consider the linear programming problem:
min
x
cTx, subject to Ax  b, x   0, (2.26)
where A 2 Rd1⇥d2. Let f(b) denote the optimal value of the linear program as a
function of b, where we use the convention that f(b) = 1 if the problem is infeasible.
Consider any b⇤ such that f(b⇤) is finite (i.e., the linear program is bounded and
feasible at b = b⇤). Then there exists a constant C > 0 such that for any b0 satisfying
f(b0) < 1, we have
|f(b0)  f(b⇤)|  Ckb0   b⇤k2.
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Proof We assume the reader has familiarity with linear programming terminology.
(For an overview of linear programming relevant to our proof, please see Chapter 6 of
Dantzig and Thapa (2006).) Without loss of generality we can drop the x   0 term
in the linear program (2.26) since these constraints can be incorporated into the set
of inequalities Ax  b. Consider the dual linear program:
max
y
bTy, subject to ATy = c, y   0.
It is bounded and feasible at b = b⇤ and at b = b0, which follows from the conditions
in the lemma. Let V ⇤ denote the set of vertices of the dual linear program, which is
non-empty, finite, and only depends on A and c (and does not depend on b). Since
the optimal value of the dual problem occurs at a vertex, it equals max{yT b : y 2 V ⇤},
for any vector b for which the linear program is bounded and feasible (which includes
the cases b = b⇤ and b = b0).
By strong duality, for each b 2 {b0, b⇤}, the optimal value of the primal (original)












|yT (b0   b⇤)|  max
y2V ⇤
kyk2kb0   b⇤k2,
where the last inequality follows from the Cauchy-Schwartz inequality. The lemma is
proved for C = max
y2V ⇤ kyk2, which is finite since V ⇤ is non-empty and has a finite
number of elements. ⇤
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Lemma 2 Let P0 be the true joint distribution on (X, YC , YT ). Suppose Assumptions
1 and 2 hold. Then ✏
k
p! 0 for any k, as n ! 1.
Proof In this proof, we will show that lim
n!1 P0(|✏k   0| > ⌘) = 0 for any ⌘ > 0.
With regards to notation used throughout this proof, limits are taken as n ! 1.
For example, p! signifies convergence in probability as n ! 1. Define 1
E
to be













, where y = (y1, y2, .., yM)T .
Choose any k = 1, .., K. Fix n 2 N. Consider the following linear program,
referred to as LP:
min
x
cTx, subject to Ax  b, x   0.
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By Assumption 1, f(b⇤) = 0. When b = bn, LP is equivalent to the linear program
for ✏
k
, so f(bn) = ✏
k
 1. By Lemma 1, there exists a constant C > 0 such that
|f(b)  f(b⇤)|  Ckb  b⇤k2 for any b such that f(b) < 1. This means that |f(bn) 
f(b⇤)|  Ckbn   b⇤k2.
Choose any ⌘ > 0. Then
P0(|✏k   0| > ⌘) = P0(|f(bn)  f(b⇤)| > ⌘)  P0
⇣





It follows from the Weak Law of Large Numbers that bn converges to b⇤ in probability,
and so the right side of the above display converges to 0 as n ! 1, completing the
proof of the lemma.
⇤
Theorems 1 and 3 imply that, if P0 is consistent with R, then the probability










satisfy the inequalities in Theorem 1. This
means that including a baseline variable or restriction can only improve (or leave
unchanged) the limiting value of the bound estimators. However, at a given sample
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size, neither the plug-in estimators from Section 2.4.1 nor the above estimators are
guaranteed to satisfy the corresponding inequalities in Theorem 1.
2.4.4 Non-regularness of the Proposed Estimator
Our estimator can be non-regular when the parameter (representing the lower or
upper bound) is 0 or 1, which also occurs for Gadbury et al. (2004); Fan and Park
(2009, 2010). Furthermore, our estimator can be non-regular at boundary cases as
defined in the last paragraph of Section 2.4.1. Intuitively, non-regularity means that
the asymptotic distribution of the estimator can change dramatically under small
perturbations of the data generating distribution. Formally, an estimator b 
n
of   is
non-regular if, for some sequence of distributions P (n) satisfying
p
n||P (n)   P0|| =









  (P0)) under P0, where || · || is total variation distance (Durrett, 2010).
To show an example of non-regularity for our problem, consider a binary outcome.
Let P0 be the unique joint distribution on (YC , YT ) satisfying: P0(YC = y, YT = y) =
0.5 for each y 2 {1, 2}, and P0(YC 6= YT ) = 0. The lower bound  l(P0) is 0. Let the







converges to max{N(0, 1), 0}. The proof is presented at the end of this section. Let























n||P (n)   P0|| is O(1).
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(P (n))) under P (n) (right panel), for n = 100, 1000, 10000, and 1000000.
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Proof Consider any positive integer n. By Section 3.6 in Durrett (2010),












































n||P (n)   P0|| = 1. Since n is an arbitrary positive integer, we
conclude that
p










(P (n))) converges to max{N(0, 1), 1},
not max{N(0, 1), 0}. The proof is shown at the end of this section. Intuitively,
the sequence P (n) is like P0 except it makes the small perturbation 1/
p
n to the
marginal distribution under control, which results in a strikingly different limit dis-
tribution than under P0. Figure 2.3 illustrates the above behavior using simula-












(P (n))) under P (n) (right panel), for n = 100, 1000, 10000, and 1000000.
The results are consistent with the theoretical results that the distribution in the left
panel converges to max{N(0, 1), 0} and the distribution in the right panel converges
to max{N(0, 1), 1}. The N(0, 1) density curve is superimposed on the two plots
where n = 1000000. The point mass at 0 (-1) in the left (right) plot is approximately
0.49 (0.16). In this example, the above limit distributions are the same if we modify
the parameter and estimator to incorporate the no harm assumption.
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(P0)) under P0, followed






(P (n))) under P (n).
Proof (Limiting distribution of
p







(P0)) converges in distribution to max{N(0, 1), 0}.




























































































































































































Define g((x, y, z)T ) = y/z  x/(1  z). By the Multivariate Delta Method (Rohde,
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By applying the Continuous Mapping Theorem (van der Vaart, 2000) with h(x) =

























(2), 0} d! max{N(0, 1), 0}.
Since  
l













d! max{N(0, 1), 0}.
⇤
Proof (Limiting distribution of
p







(P (n))) converges in distribution to max{N(0, 1), 1}.
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m=1 E [||Zn,m||21(||Zn,m|| > ✏)] = 0 is
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d! N (0, 1) .


















m=1 1(Am = 1)
◆
d! N(0, 1).


























d! max{N(0, 1), 1}. This simplifies
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2.4.5 Inference Based on the Proposed Estimator
The impact of non-regularity is that confidence intervals based on the standard
nonparametric bootstrap (called the n-bootstrap) are typically inconsistent, as shown
by Bickel et al. (1997). They recommend to remedy this by using the m-out-of-n
bootstrap, where each bootstrap replicate data set is generated by resampling m  n
participants with replacement. Fan and Park (2010) use m-out-of-n bootstrap to
construct confidence intervals, and report that coverage probability is relatively close
to the desired 95% level in their simulations. We also use the m-out-of-n bootstrap
in our simulations in Section 2.6. Just as Fan and Park (2010), we select m based
on Bickel and Sakov (2008), whose algorithm aims to achieve pointwise asymptotic
consistency and efficiency. Consistency requires that in cases where the n bootstrap
is inconsistent (as can happen when the estimator is non-regular, for example), that
46
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the growth rate of m be slow enough (e.g., m/n ! 0 and m ! 1). Efficiency
requires that when the n bootstrap is consistent, that the growth rate of m be of
similar order as n. The procedure that we apply to choose m is as follows:
1. The candidates for m are taken to be m
j
= [0.95jn], j = 0, 1, 2, ..., that satisfy
m
j
  20. The function [·] is the ceiling function.
2. For any given candidate m
j
, we generate 5000 bootstrap data sets each by
resampling m
j
participants, with replacement, from the data set. The lower
bound estimate is computed for each bootstrap data set. If any of the 5000
lower bound estimates are undefined, m
j
is eliminated from consideration; an
undefined bound estimate indicates that there were no control or no treatment
participants in the bootstrap data set, and this suggests the candidate m
j
is
too small. Otherwise, let the function Q⇤
mj
be the vector of 5000 lower bound
estimates from smallest to largest.




denote the candidate that is the next smallest after m
j









where the function ⇢ takes the absolute value of the difference between the two
vectors and returns the maximum element. This value m is used to construct
the CI for the lower bound. If multiple m
j
achieve the minimum, the largest
value is chosen. The argmin is taken over only m
j
that are under consideration.
An analogous procedure is used to choose the value m for constructing the CI
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for the upper bound.
For a given data generating distribution, the m-out-of-n bootstrap has asymptot-
ically correct coverage probability (called pointwise consistency) for our problem if
both m ! 1 and m/n ! 0 as n ! 1; this result follows from Theorem 1 of Bickel
et al. (1997). The convergence rate of m is difficult to determine, due to the complex-
ity of the Bickel and Sakov (2008) algorithm. It is difficult even to establish pointwise
consistency; the proof of this property in Bickel and Sakov (2008) requires six assump-
tions that would be very hard to verify from data. Therefore, just as for Fan and Park
(2010), the resulting confidence intervals may fail to be pointwise consistent. Fan and
Park (2009, Section 5.2) give an alternative approach requiring substantially weaker
(but still hard to verify) assumptions. An important problem addressed in Chapter 3
is to construct confidence intervals that overcome the above issues. Despite the lack
of asymptotic guarantees, the m-out-of-n bootstrap has relatively good performance
in our simulation studies at sample size 500 or greater.
Our estimator can have substantial bias (in terms of its contribution to the mean
squared error) in finite samples (Section 2.6), just as the estimators of Fan and Park
(2009, 2010). They derive a first-order bias correction for their estimator. In our case,
deriving a general bias correction would be quite challenging since our estimator does
not have a simple analytic form (and instead is represented as a solution to linear
programs).
Define the asymptotic distribution of our estimator  R
l
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as n ! 1 under P0. If this is not a boundary case (as defined in Section 2.4.1), then
the asymptotic distribution is the maximum of the components of a mean zero (pos-
sibly degenerate) multivariate normal distribution with covariance matrix depending
on P0 and R. For a boundary case, the asymptotic distribution can be more complex
since then
p
n✏ has a non-degenerate limit distribution and affects the asymptotic
distribution of our estimator. It is an open problem to precisely characterize the
limit distribution in boundary cases; however, even if this were solved, it would not
immediately lead to a confidence interval procedure since the limit distribution would
generally depend on the unknown P0.
2.5 MISTIE Application using Bound Esti-
mator from Section 2.4.2
Using MISTIE II, we estimate bounds on the fraction of ICH patients who benefit
from treatment relative to control. We apply the estimators from Section 2.4.2.
2.5.1 30- and 180-day mRS scores
For both 30- and 180-day mRS, four types of sharp lower/upper bounds are esti-

















R considered are Benefit  d levels and Harm  d levels. The value d is varied from 1
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to 5 for the former, and 0 to 5 for the latter. The baseline variable X is stroke sever-
ity as measured by the National Institutes of Health Stroke Scale (NIHSS), where
a stroke is classified as non-severe if the score  20 and severe otherwise (Kreutzer
et al., 2011). When estimating bounds for a given outcome (e.g., 180-day mRS),
we exclude participants who are missing that outcome; for both mRS outcomes, we
exclude the single patient with missing baseline NIHSS score. The resulting sample
sizes are 53 treatment and 39 control participants for 30-day mRS, and 52 treatment
and 37 control participants for 180-day mRS. The top panel of Figure 2.4 shows
the empirical distributions under treatment and control of 30-day mRS. The mid-
dle panel shows the empirical distributions within the non-severe stratum, and the
bottom panel shows the empirical distributions within the severe stratum. Figure
2.5 for the 180-day mRS outcome is organized analogously. The proportion in each
subpopulation is estimated by the corresponding sample proportion of MISTIE II
participants after excluding participants as described above.
The bound estimates for 30-day mRS and 180-day mRS are plotted in Figures 2.6
and 2.7, respectively. Each bar ranges from the lower to the upper bound estimate.
A bar is grey if the baseline variable is not used, and black otherwise. The restriction
imposed, if any, is indicated on the x-axis. For conciseness, restrictions whose grey
and black bars are identical to those under no restrictions are excluded from these
figures. For grey bars, the value of ✏ (defined in Section 2.4.2) is listed above the bar,
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1 nT = 53 , nC = 39 treatment
control
1 2 3 4 5 6 7
Subpopulation with non−severe stroke
mRS score
0
1 nT = 21 , nC = 18
1 2 3 4 5 6 7
Subpopulation with severe stroke
mRS score
0
1 nT = 32 , nC = 21
Figure 2.4: Empirical Distribution of 30-day mRS Score under Treatment and Con-
trol.
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1 nT = 52 , nC = 37 treatment
control
1 2 3 4 5 6 7
Subpopulation with non−severe stroke
mRS score
0
1 nT = 21 , nC = 17
1 2 3 4 5 6 7
Subpopulation with severe stroke
mRS score
0
1 nT = 31 , nC = 20
Figure 2.5: Empirical Distribution of 180-day mRS Score under Treatment and
Control.
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Figure 2.7: Bounds Estimates for 180-day mRS Score, using Method from Sec-
tion 2.4.2.




is [0.07,0.61] for 30-day mRS, and [0.10,0.73]
for 180-day mRS. The widths of these estimated bounds, i.e., the difference between
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the upper and lower bound estimates, are 0.54 and 0.63, respectively. Restrictions
and the baseline variable can narrow the width of the estimated bounds. For 180-day
mRS, the width narrows by 0.17 under Benefit  1, 0.31 under Harm  1, and 0.55
under no harm, relative to no restrictions. These reductions are absolute differences
in widths, as is the case throughout this chapter. Without restrictions, the baseline
variable narrows the width by 0.19 for 30-day mRS, and 0.12 for 180-day mRS. With
the restriction R = {Harm  2}, the upper bound estimate with the baseline variable
( R,X
u
= 0.63) is slightly above that without the baseline variable ( R
u
= 0.62). This
can occur since, as mentioned in Section 2.4.2, the bound estimators need not obey
the corresponding inequalities in Theorem 1.
In Figures 2.6 and 2.7, there are five cases in which ✏ > 0 or some ✏
k
> 0.
(The value ✏ is the analog of ✏
k
when no baseline variable is used. It was defined in
Section 2.4.2.) We point out two features. First, these bound estimates may not be
contained within the interval formed by estimates under a less stringent restriction.
For 30-day mRS, the lower bound estimate under R = {no harm} is  R
l
= 0.03,
which is below the lower bound estimate  R
0
l
= 0.07 under the weaker restriction
R0 = {Harm  1}. This behavior is either due to a boundary case (see Section
4), small sample performance of the estimator, or the data generating distribution
not satisfying the no harm assumption. In the third case, the bound estimators
may be inconsistent. Second, for a given restriction, an upper bound estimate can
be much larger, or a lower bound estimate much smaller, with the baseline variable
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than without it. For 180-day mRS, under the restriction R = {no harm}, the upper
bound estimate is  R
u
= 0.18 without the baseline variable, and  R,X
u
= 0.54 with it.
One possible cause for this behavior is that the no harm assumption is false. In this
case, the parameter  R
u
could be well-defined while  R,X
u
is undefined, as discussed in
Section 2.3.2. Then  R
u
could be much smaller than  R,X
u
, even at large sample sizes.
2.5.2 Reduction in clot volume
Reduction in clot volume (RICV) is the difference between clot volume at baseline
and end of treatment, as defined by Mould et al. (2013). In MISTIE II, the observed
RICV range was [-2.57, 75.45] mL under treatment, and [-14.86, 12.01] mL under
control. For any given baseline clot volume, the larger the RICV, the better.
We discretize RICV to an ordinal outcome. The appropriate bin length depends
on the change in RICV that would be a clinically meaningful difference. If an im-
provement of 5 mL or more is a clinically meaningful benefit, the bin length can be set
to 5 mL. Based on personal communications with neurologist Daniel Hanley, there
currently is not enough biologic evidence to define a clinically meaningful change.
Therefore, we consider various bin lengths, including 2, 5, 10, and 20 mL. We name
the corresponding ordinal outcomes RICV2, RICV5, RICV10, and RICV20, respec-
tively. Let y be (continuous) reduction in clot volume. We define RICV2, RICV5,
RICV10, and RICV20 as follows:
Definition of RICV2
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• Level 1: y < 0 mL
• Level 2: 0 mL  y < 2 mL
• Level 3: 2 mL  y < 4 mL
• Level 4: 4 mL  y < 6 mL
• Level 5: 6 mL  y < 8 mL
• Level 6: 8 mL  y < 10 mL
• Level 7: 10 mL  y < 12 mL
• Level 8: 12 mL  y < 14 mL
• Level 9: 14 mL  y < 16 mL
• Level 10: 16 mL  y < 18 mL
• Level 11: 18 mL  y < 20 mL
• Level 12: y   20 mL
Definition of RICV5
• Level 1: y < 0 mL
• Level 2: 0 mL  y < 5 mL
• Level 3: 5 mL  y < 10 mL
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• Level 4: 10 mL  y < 15 mL
• Level 5: 15 mL  y < 20 mL
• Level 6: y   20 mL
Definition of RICV10
• Level 1: y < 0 mL
• Level 2: 0 mL  y < 10 mL
• Level 3: 10 mL  y < 20 mL
• Level 4: y   20 mL
Definition of RICV20
• Level 1: y < 0 mL
• Level 2: 0 mL  y < 20 mL
• Level 3: y   20 mL
We now present the procedure and results of the RICV5 analysis. The analysis
procedure is analogous for RICV2, RICV10, and RICV20. The fraction who bene-
fit, with respect to RICV5, is the fraction who would have a higher RICV5 under
treatment than under control. We estimate sharp bounds (i)-(iv) as in Section 2.5.1.
The restrictions R considered are Benefit  d levels and Harm  d levels, where d is
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varied from 1 to 4 for the former, and 0 to 4 for the latter. The baseline variable X
is an indicator of the baseline clot volume being above or below the median baseline
clot volume of the MISTIE II participants (43.2 mL). There are no missing data, and
all MISTIE II participants are included in the analysis. The empirical distributions
of RICV5 under treatment and control, with and without stratifying by baseline clot
volume, are shown in Figure 2.8. While all control participants had RICV5 of 4 or
less, 74% of treatment participants had RICV5 higher than 4. This suggests that
treatment has a major effect on RICV5.
The estimated bounds on the fraction who benefit are plotted in Figure 2.9. The
values are recorded in Table 5.3 of Chapter 5. The estimated bounds are [0.82, 0.96]
with neither the baseline variable nor restrictions, and [0.83, 0.96] with only the
baseline variable. Assuming Benefit  d levels (d = 1,2, or 3), the bound estimates
are much wider than without restrictions. The values ✏ and ✏
k
range from 0.12 to 0.43.
Large values of ✏ or ✏
k
raise doubts about the validity of the restrictions; it is an area
of future work to construct formal hypothesis tests, to determine with high confidence
whether a large observed value of ✏ or ✏
k
can be explained by chance variation or is
due to violations of the restrictions. The restrictions on harm are not shown because
the results are the same as under no restrictions.
The results for RICV2, RICV10, and RICV20 are shown in Tables 5.4, 5.5, 5.6 and
Figures 5.1, 5.2, 5.3 of Chapter 5. The bound estimates are almost identical among
RICV2, RICV5, and RICV10. The estimates for RICV20 are smaller because many
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Figure 2.8: Empirical Probability Mass Functions of RICV5 under Treatment and
Control.
improvements that would be benefits at the smaller bin lengths no longer qualify
when the bin length is 20 mL.
Using m-out-of-n bootstrap, we compute two-sided 95% CI’s for the lower bound
 
l
and the upper bound  
u
for all outcomes. To construct these CI’s, we follow the
procedure previously presented in Section 2.4.5 to choose m and apply the percentile




are [0, 0.29] and [0.42, 0.76] for 30-day mRS; [0, 0.31]
and [0.50, 0.85] for 180-day mRS; [0.71, 0.92] and [0.90, 1] for RICV5. These CI’s
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Figure 2.9: Bound Estimates for RICV5, using Method from Section 2.4.2.
should be interpreted with caution. The m-out-of-n bootstrap can have lower than
nominal coverage at n = 100 (Section 2.6), and the sample size of MISTIE II is
n = 96.
2.6 Simulation Studies
2.6.1 Simulations without a Baseline Variable
Two outcomes are separately considered: RICV5 and a binary outcome. No base-
line variable is used. For RICV5, the data generating distributions under treatment
and control are the empirical distributions in MISTIE. No restrictions are made. The
bounds are (ψl, ψu) = (0.82, 0.96).
For the binary outcome, the data generating distribution is P0(YT = y) = P0(YC =
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y) = 0.5 for y 2 {1, 2}. We consider the cases of no restrictions and the no harm








) = (0, 0), respectively,
where R = {no harm}. We call these two cases binary (no restrictions) and binary
(no harm).
For each case, we simulate 10,000 randomized trials each with n participants
(n2 in treatment,
n
2 in control). We consider n = 100, 500, and 1000, respectively.
Using each simulated trial, the estimators from Section 2.4.2 are computed. Also, we
compute a two-sided 95% CI for the lower bound and a separate two-sided 95% CI for
the upper bound, using n-bootstrap and m-out-of-n bootstrap. For n-bootstrap, we
generate 10,000 replicated data sets by resampling n participants, with replacement,
from the simulated trial. The percentile method is used to get the 95% CI. For m-
out-of-n bootstrap, we generate the 10,000 replicated data sets each by sampling m
participants with replacement. The choice of m follows the procedure presented in
Section 2.4.5.
Table 2.1 shows the empirical bias and standard error of the bound estimators
for each case. Columns labeled “lower" give results for the lower bound estimator.
Columns labeled “upper" give results for the upper bound estimator. Bias is negligible
for RICV5. For the binary outcome, bias is substantial; the bias contribution to the
mean squared error, as a percentage, ranges from 31 to 34%. The results for the lower
bound in the no restrictions case and for both bounds in the no harm case are almost




, and  R
u
are identical if the outcome is binary and
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Table 2.1: Bias and Standard Error of Proposed Estimator.
Bias Standard error
Case n lower upper lower upper
RICV5 100 0.002 0.000 0.055 0.027
500 -0.000 -0.000 0.025 0.012
1000 -0.000 -0.000 0.018 0.008
Binary 100 0.040 -0.040 0.059 0.059
(no restrictions) 500 0.018 -0.018 0.026 0.026
1000 0.012 -0.013 0.018 0.018
Binary 100 0.040 0.040 0.058 0.058
(no harm) 500 0.018 0.018 0.026 0.026
1000 0.013 0.013 0.018 0.018
R = {no harm}, as proved below. Any differences in results between these estimators
are due to sampling variability.
Proof Consider a binary outcome whose two possible values are coded as 1 and 2,
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(2), it follows that ✏ > 0 because there exist no joint distribu-




and satisfy the no harm assumption.
It can be shown that ✏ = p̂C(2) p̂T (2)2 . There exists one joint distribution which satisfies
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We compare the plug-in estimator to our estimator in the binary (no harm) case,
in which they can differ due to the restriction. The plug-in estimator is undefined in
46% of simulations for n = 100, 48% for n = 500, and 49% for n = 1000. Conditional
on being well-defined, it has bias 0.074 (n = 100), 0.034 (n = 500), 0.024 (n = 1000).
Our estimator is less biased (Table 2.1) since it is equivalent to the plug-in estimator
if the latter is well-defined, and is 0 (i.e., equal to the true lower and upper bounds)
otherwise. Conditional on being well-defined, the plug-in estimator has standard
63
CHAPTER 2. ESTIMATING BOUNDS ON THE FRACTION WHO BENEFIT
Table 2.2: Coverage Probabilities and Average Widths of CI’s Constructed using
n-bootstrap and m-out-of-n bootstrap.
Coverage Average width
n- m-out-of-n n- m-out-of-n
bootstrap bootstrap bootstrap bootstrap
Case n lower upper lower upper lower upper lower upper
RICV5 100 .937 .839 .943 .848 .205 .088 .218 .093
500 .943 .941 .971 .947 .098 .046 .116 .049
1000 .950 .948 .973 .960 .070 .033 .084 .037
Binary 100 .973 .898 .987 .930 .196 .243 .231 .278
(no restrictions) 500 .975 .893 .987 .934 .088 .109 .106 .129
1000 .978 .886 .989 .927 .062 .077 .075 .092
Binary 100 .974 .974 .985 .985 .196 .196 .231 .231
(no harm) 500 .975 .975 .987 .987 .088 .088 .107 .107
1000 0.974 .974 .988 .988 .062 .062 .076 .076
error 0.061 (n = 100), 0.027 (n = 500), 0.019 (n = 1000). Our estimator has similar
standard errors (Table 2.1).
Table 2.2 shows the empirical coverage probability of the nominal 95% CI’s con-
structed using m-out-of-n and n-bootstrap. The columns labeled “lower" give results
for the CI’s for the lower bound, and columns labeled “upper" give the results for
the CI’s for the upper bound. For the binary outcome, the empirical coverage is
above 95% except for the upper bound in the no restrictions case, where coverage is
as low as 92.7% for m-out-of-n bootstrap and 88.6% for n-bootstrap. For RICV5,
empirical coverage is close to the nominal coverage, except the coverage rates for the
upper bound are ⇡ 84% when n = 100. In our simulations, m-out-of-n bootstrap has
higher coverage probability and average CI width than n-bootstrap. Fan and Park
(2010) report the coverage probabilities of n- and m-out-of-n bootstrap both have
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approximately the nominal coverage in simulations for their problem.
2.6.2 Simulation Studies with a Baseline Variable
We ran another set of simulations with a baseline variable to evaluate how subdi-
viding into more strata affects the properties of our bound estimator. We consider two
outcomes RICV5 and 180-day mRS. No restrictions are imposed for either outcome.
For RICV5, the baseline variable is baseline clot volume. Three cases are considered,
number of strata K = 2, 4, and 8. For K = 8, the eight strata are constructed using
the octiles of the MISTIE II baseline clot volumes as cutpoints. The probability of
belonging to each stratum is set as 1/8. The marginal distributions under treatment
and control for each stratum are set as the empirical distributions in MISTIE. We
get K = 4 strata by merging every two adjacent strata of K = 8. We get K = 2
strata by merging every four adjacent strata of K = 8. The stratum probabilities and





) are then (0.85, 0.96) for K = 2, (0.89, 0.96) for K = 4, and
(0.89, 0.95) for K = 8. The bounds slightly narrow with higher K; the bound widths
are 0.11 (K = 2), 0.07 (K = 4), and 0.06 (K = 8).
For 180-day mRS, the baseline variable is NIHSS score, which can be any integer
from 1 to 42. We consider K = 2, 3, and 4. For K = 4, the four strata are minor
stroke = 1-4, moderate stroke = 5-15, moderate/severe stroke = 16-20, and severe
stroke = 21-42 (Kreutzer et al., 2011). The stratum probabilities are set to be those
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in MISTIE, i.e., 0.03, 0.12, 0.27, and 0.57, respectively. For each of these K = 4
strata, the marginal distributions under treatment and control are set to be those
observed in MISTIE. For K = 3, the three strata are obtained by merging the first
two strata of K = 4. For K = 2, we merge the first three strata of K = 4. The
stratum probabilities and marginal distributions for K = 2, 3 are derived using those




) are then (0.14, 0.65) for K = 2, (0.16,
0.59) for K = 3, and (0.20, 0.59) for K = 4. The bounds narrow with higher K; the
bound widths are 0.51, 0.43, and 0.39, respectively.
The simulations are implemented as follows. For a given outcome and value K, we








We consider sample size n = 100, 500, and 1000, respectively. We generate a par-
ticipant’s stratum membership X by taking a random draw from the K strata, in
concordance with the stratum probabilities. For a participant assigned to control
(treatment), the observed outcome Y is then generated by taking a random draw
from the marginal distribution under control (treatment) for the stratum to which





Section 2.4.2 are computed.
The results are shown in Table 2.3 (RICV5) and Table 2.4 (180-day mRS). Each
table is organized in the following way. In the “Number of Strata” column, the number





The “Percent with undefined estimates" column gives the percent of simulations with
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lower upper lower upper
2 100 0 0.013 -0.000 0.047 0.027
(0.85, 0.96) 500 0 0.001 0.000 0.022 0.012
1000 0 0.000 0.000 0.016 0.008
4 100 0 0.004 -0.001 0.043 0.027
(0.89, 0.96) 500 0 -0.000 -0.000 0.020 0.012
1000 0 -0.000 0.000 0.014 0.008
8 100 1.9 0.011 -0.005 0.044 0.034
(0.89, 0.95) 500 0 0.002 0.000 0.019 0.014
1000 0 0.001 -0.000 0.014 0.010







lower upper lower upper
2 100 0 0.057 -0.007 0.073 0.070
(0.14,0.65) 500 0 0.021 0.000 0.035 0.033
1000 0 0.013 0.000 0.025 0.024
3 100 0.05 0.052 -0.005 0.073 0.071
(0.16, 0.59) 500 0 0.013 -0.001 0.036 0.032
1000 0 0.007 -0.000 0.026 0.022
4 100 32.9 0.040 -0.013 0.073 0.071
(0.20, 0.59) 500 0.07 0.014 -0.000 0.035 0.031
1000 0 0.007 -0.001 0.025 0.022
undefined bound estimates. Bound estimates are undefined if no treatment or no
control subjects are observed for some stratum. Bias and standard error are computed
excluding the simulations with undefined bound estimates. Within the “Bias” and
“Standard Error” columns, the “lower” and “upper” subcolumns specify whether the
results are for the lower or upper bound estimator.
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The percent of simulations with undefined estimates is small in most cases. How-
ever, over 30% of simulations had undefined estimates for the K = 4, n = 100 case
of 180-day mRS. This is not surprising since the probability of being in the first of
the K = 4 strata is only 0.03. With the small trial size of n = 100, it is likely to
observe no treatment or no control subjects in the first stratum. Interestingly, the
bias and standard error of our estimator (conditional on it being well-defined) are not
adversely affected (and sometimes can be even better), when the baseline variable is
discretized finely compared to coarsely. For RICV5, there is little bias for K = 2, 4,
and 8. The standard errors are similar among the various K, except K = 8 has a
slightly higher standard error at n = 100 than the other K. For 180-day mRS, the
standard errors are also very similar among the various K. However, there are some
small differences in bias. For the lower bound, there is non-negligible bias and K = 2
tends to have more bias than the higher values of K at fixed sample size. For the
upper bound, there is very little bias for all K, but K = 4 has slightly more bias
than the smaller values of K at n = 100. Bias, standard error, and the probability of
undefined estimates may be highly dependent on the data generating distribution.
2.7 Discussion
In the MISTIE application, the interval corresponding to the lower and upper
bound estimates is wide for the mRS outcome, and narrow for RICV. Depending on
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the outcome, the proposed estimator of the bounds can be informative.









) = (0.10, 0.18)
when R = {no harm}. The latter bound estimates, though much closer together than
in the former case due to the lower and upper bound estimates being much closer
together, are only valid if the no harm assumption is true. This can be appropriate in
some clinical settings but not in others. It is possible to generate evidence against the
restriction being true by considering the value of ✏. Though certain deviations from
the restrictions may be detectable through ✏, other deviations may not be. One may
view the bound estimators under nested sets of more stringent restrictions as being
a sensitivity analysis to examine how much information on the fraction who benefit
would result under different types of assumptions on harm/benefit.
Our method can be applied to a continuous outcome that has been discretized.
Discretization should be done such that a change from one level to the next is clinically
meaningful. We focus on the case where there are relatively few levels compared to
the sample size; it is an open problem to handle the case where the number of levels
is not small relative to the sample size.
2.8 Software
Our code is available online at https://github.com/emhuang1/fraction-who-benefit.
In the “demo” folder, we demonstrate how to analyze a simulated data set using the
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code. The results from analyzing the simulated dataset are printed here.
> est1
[1] 0.1322825 0.7673190 0.0000000
> est2
[1] 0.1322825 0.2143657 0.0000000
> est3
[1] 0.1322825 0.7673190 0.0000000
> est4
[1] 0.2143657 0.2143657 0.0000000
> est5
[1] 0.12720555 0.73380326 0.17922078 0.73636364 0.00000000
0.07723013 0.73134328 0.00000000
> est6
[1] 0.125296456 0.210329557 0.175324675 0.262337662 0.001948052
0.077230128 0.160360986 0.000000000
> est7
[1] 0.13021492 0.73380326 0.17922078 0.73636364 0.00000000
0.08313086 0.73134328 0.00000000
> est8




lower bound 0.02649258 0.2451933 300
upper bound 0.60000000 0.8253968 120
The results “est1” through “est8” are the bound estimates for a simulated data set
under eight different settings, described in the analyzeDataset.R code in the “demo”
folder on GitHub. The printed output for “result” gives the 95% two-sided CI for  
l
and the 95% two-sided CI for  
u




Constructing a Confidence Interval
for the Fraction who Benefit Using a
Randomized Trial
3.1 Abstract
The fraction who benefit from treatment is defined as the proportion of patients
whose potential outcome under treatment is better than that under control. Statis-
tical inference for this parameter is challenging since it is only partially identifiable,
even in our context of a randomized trial. We propose and evaluate a new method
for constructing a confidence interval for the fraction who benefit, when the outcome
is ordinal-valued (with binary outcomes as a special case). This confidence interval
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procedure is proved to be pointwise consistent. Our method does not require any
assumptions about the joint distribution of the potential outcomes, although it has
the flexibility to incorporate a wide range of user-defined assumptions. A potential
advantage of our approach is that, unlike existing confidence interval methods for
partially identified parameters (such as m-out-of-n bootstrap and subsampling), we
do not need to select m or the subsample size, which is generally a challenging prob-
lem. Our method is based on a stochastic optimization technique involving a second
order, asymptotic approximation that, to the best of our knowledge, has not been
applied to biomedical studies. This approximation leads to statistics that are solu-
tions to quadratic programs, and so they can be computed efficiently using existing
optimization tools. In all of our simulations, our method attains the nominal coverage
probability or higher, and can have substantially narrower average width compared
to the m-out-of-n bootstrap. We also apply our method to a completed trial data set
of a new surgical intervention for severe stroke.
3.2 Introduction
The fraction who benefit from treatment is the proportion of patients whose po-
tential outcome under treatment is better than that under control. In other words,
it is the proportion who would be better off with treatment. This fraction may be
of interest to patients and care providers deciding between treatment and control. It
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may also be informative to medical researchers; for example, a small fraction indi-
cates that an exclusive subgroup benefits and resources should be devoted towards
identifying it. We aim to draw inferences about the fraction who benefit, using a
randomized trial.
In general, the fraction who benefit (sometimes abbreviated as “the fraction”)
is non-identifiable from observed data, even in the randomized trial context. This
occurs because only one potential outcome can be observed per patient. Typically,
identifiability of the fraction necessitates strong, untestable assumptions on the joint
distribution of the potential outcomes, such as independence of the potential outcomes
within a person. We do not require any assumptions on the joint distribution and
only consider assumptions based on subject matter knowledge. Since the fraction
is generally non-identifiable in this setting, constructing a confidence interval is a
challenging problem.
An existing confidence interval procedure for our problem involves applying the m-
out-of-n bootstrap to estimators of lower and upper bounds (which are identifiable)
on the fraction who benefit. The m-out-of-n bootstrap is a generalization of the
standard nonparametric bootstrap, where bootstrap replicate data sets are generated
by resampling m patients with replacement for m  n. The m-out-of-n bootstrap
is recommended because the bound estimators for our problem can be non-regular
(Huang et al., 2017), and the standard bootstrap can be inconsistent in such cases.
Another existing method for constructing confidence intervals is the subsampling
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approach of Romano and Shaikh (2008). Subsampling is similar to the m-out-of-n
bootstrap, except resampling is done without replacement. A challenge in using m-
out-of-n bootstrap or subsampling is how to select m to achieve good performance.
We propose a new confidence interval method that avoids having to select m.
Through simulation, we compare our method to the m-out-of-n bootstrap with
respect to coverage probability and average width. In all cases, our method has
coverage probability at or above the nominal level, while the m-out-of-n bootstrap
sometimes has coverage probability below the nominal level. In some cases, our
method achieves substantially narrower average width than the m-out-of-n bootstrap,
e.g., reduction in average width of 40%. Our method has good coverage probability
even in cases where the lower and upper bound parameters are non-differentiable
functions of the marginal distributions under treatment and control, as shown in
Section 3.6.
We apply our method to the CLEAR III (Clot Lysis: Evaluating Accelerated
Resolution of Intraventricular Haemorrhage III) randomized trial of a new surgical
treatment for stroke, which had a sample size of 500 patients (Hanley et al., 2017).
Outcomes included disability measured by the modified Rankin Scale and death.
As examples of the output of our confidence interval procedure, the 95% confidence
interval for the fraction who benefit is [0.01,0.18] for the outcome 30-day mortality,
[0.05,0.34] for 180-day mortality, [0,0.64] for 30-day disability, and [0.03,0.86] for 180-
day disability.
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Our confidence interval procedure is based on representing the problem as a
stochastic optimization problem. Stochastic optimization involves maximizing or min-
imizing the expected value of a function of unknown parameters and random variables,
based on repeated observations of the random variables (data). As a simple example,
M-estimators can be represented in terms of solving stochastic optimization problems
(van der Vaart, 2000, Chapter 5). Our problem is substantially harder, since its for-
mulation as a stochastic optimization problem involves a set of additional constraints
on the parameter space (specifically, that the parameter lies within a polyhedron).
When the optimal solution converges to a point on the boundary of the parameter
space, the resulting statistics are generally not asymptotically normal; this rules out
standard confidence interval procedures, many of which require asymptotic normality.
Shapiro et al. (2014) present general approaches for deriving the asymptotic dis-
tributions of such challenging stochastic optimization problems. To the best of our
knowledge, these general approaches have not previously been used to solve problems
arising in biomedical studies. We tailor one such approach to solve our problem, using
a second order, asymptotic approximation of the objective function. We provide a
self-contained proof of the validity of our method, which can be understood without
requiring knowledge of stochastic optimization.
The statistic derived using the above approach can be computed using quadratic
programming, i.e., minimizing a quadratic function of the data and parameters sub-
ject to linear equality and inequality constraints on the parameters. We used the
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“quadprog” solver in MATLAB 2013B. The computing time of our method (after
preprocessing) is independent of the sample size, but dependent on the width of the
confidence interval and the number of levels for the ordinal outcome (larger width and
fewer levels take less time). Each confidence interval in the CLEAR III application
was computed between 4 and 8 minutes. This running time can be further reduced
through parallelization.
Section 3.3 provides an overview of the previous work on the fraction. In Section
3.4, we describe the data generating distribution and state assumptions that are used
throughout the paper. Our new method is presented in Section 3.5, including proofs
of its asymptotic properties. We evaluate the method through simulation in Section
3.6. It is applied to the CLEAR III randomized trial in Section 3.7. Future work is
discussed in Section 3.8.
3.3 Related Work
In general, the fraction who benefit is non-identifiable without making untestable
assumptions about the joint distribution of the potential outcomes. There has been
work on deriving and estimating bounds on this parameter in our context of ordinal
outcomes (Borusyak, 2015; Lu et al., 2016; Huang et al., 2017).
To construct a confidence interval for the fraction who benefit, one could use the
bound estimators proposed in Huang et al. (2017) and apply the m-out-of-n bootstrap
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to them. Romano and Shaikh (2008) propose a general confidence interval method
based on subsampling for partially identified parameters, such as the fraction who
benefit. Under the subsampling condition (i) in Theorem 3.4 of their paper, Romano
and Shaikh (2008) prove pointwise consistency of their confidence interval method.
However, it is difficult to establish whether this condition holds in our problem.
Other parameters that contrast the distribution of an ordinal outcome under treat-
ment versus control include the number needed to treat and the parameter in a re-
sponder analysis (Snapinn and Jiang, 2007). However, these parameters require that
the ordinal outcome be dichotomized into “success” or “failure”. For example, in one
analysis of the CLEAR III trial, the modified Rankin Scale outcome was considered a
“success” if it was in the range 0-3 (Hanley et al., 2017). The parameter of interest in
a responder analysis is the difference between the population proportions who have a
successful outcome under treatment versus control, where success can be a function
of baseline variables. The number needed to treat is the reciprocal of this difference
(Gordis, 2009). A downside to dichotomization of the outcome is that improvements
not crossing the dichotomization threshold are ignored. The fraction who benefit
considers the full ordinal scale.
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3.4 Notation, Parameter Definition, and As-
sumptions
3.4.1 Parameter Definition
Consider an ordinal outcome with a finite number of levels, L. Without loss of
generality, we assume that the levels are numbered as integers from 1 to L, in order
of least to most favorable. Denote Y
T
as the potential outcome under treatment and
Y
C







denote the probability that Y
C





= P0(YC = i, YT = j). We say that a patient benefits from treatment compared to


















who benefit from treatment, our parameter of interest, is:






We propose a method to construct a confidence interval for the parameter  0, which
does not require assumptions about the joint distribution P0. The method can incor-
porate restrictions on the support of P0, supplied by the user based on subject matter
knowledge. Support restrictions are assumptions that certain potential outcome pairs
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(i, j) are not possible, i.e., ⇡
i,j
= 0. The no harm assumption (⇡
i,j
= 0 if i > j) is
one example. For conciseness, we refer to support restrictions as restrictions. The
user specifies restrictions through a function g : L ⇥ L ! {0, 1}, where L is the set
of integers from 1 to L. For any given input (i, j), the user sets g(i, j) to 0 if she/he
assumes that ⇡
i,j
= 0, and 1 otherwise. If no restrictions are made, the function g














= j) = 0 if g(i, j) = 0}. (3.2)
Assumption 3 The user-defined support restrictions are correct, i.e., P0 2 R.
Incorrect assumptions can lead to poor coverage probability of our method and the
m-out-of-n bootstrap, as shown in Section 3.6.
3.4.2 Observed Data
We construct our confidence interval using data from a randomized trial. Let n




denote the participant’s treatment assignment (1 if treatment and 0 if control) and




), i = m, .., n,
are fully observed. Other assumptions include the following:
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is an independent, identically distributed draw from the unknown joint distribution
P0.
Assumption 5 The treatment assignments, A
m
, m = 1, .., n, are independent, iden-





















Assumption 5 is satisfied by a simple randomized trial design (Friedman et al., 2010).
The value ✓ is the probability of being assigned to treatment, which is known and
should not be 0 or 1. Assumption 6 connects observed outcomes to potential outcomes
and is called the consistency assumption.
3.4.3 Non-identifiability of the Fraction who Benefit




), m = 1, .., n, are in-
dependent and identically distributed. Let (A, Y ) denote the random vector corre-
sponding to a generic participant in the randomized trial. The vector (A, Y ) for





) which is partially unobserved. Let P
obs
denote the pop-
ulation distribution on the observed data vector (A, Y ). By Assumption 5, we have
P
obs
(A = a) = ✓a(1   ✓)1 a. Let the vector  ⇤ = ( ⇤01, ..,  ⇤0L,  ⇤11, ..,  ⇤1L) denote the
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marginal distributions of the potential outcomes under treatment and under control,
where  ⇤0y = P0(YC = y) and  ⇤1y = P0(YT = y) for all y in L. By Assumptions 5 and
6, we have that for all y 2 L:
 ⇤0y = P0(YC = y) = Pobs(Y = y|A = 0), (3.3)
 ⇤1y = P0(YT = y) = Pobs(Y = y|A = 1).
This implies that the marginal distributions of the potential outcomes are identifiable.
Because only one potential outcome is observed per participant, the fraction who
benefit  0 is typically non-identifiable from observed data. However, the marginal









) denote the sharp lower and upper bounds on the fraction, given the


















) : P has marginal distributions equal to  ⇤ and P 2 R}.
These bounds are functions of P
obs
due to their dependency on  ⇤, and are identifiable
because  ⇤ is identifiable. For conciseness, we suppress the dependency on P
obs
. The
bounds are discussed in Huang et al. (2017). The fraction who benefit  0 must be









some joint distribution P 2 R that has marginals  ⇤ and with fraction who benefit
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) equal to  . Intuitively, the marginal distributions and restrictions rule




] but candidates inside the range are not
ruled out.
We use the following definition for pointwise consistency from Romano and Shaikh
(2008) tailored to our problem.
Definition 1 A confidence set CS
n
for  0 is pointwise consistent at level 1 ↵ if, for
any data generating distribution P
obs



















)   1  ↵. (3.4)
Pointwise consistency is that, if one were to consider an arbitrary data generating
distribution P
obs











includes  with at least 1   ↵ probability when n is large. This is a de-









)] and the observed data distribution provides no information on
where it lies within that range.
3.5 Proposed Method
We construct a 95% confidence set for the fraction who benefit  0 through hy-
pothesis test inversion. We consider candidate values of  on a grid on [0, 1]. In
our simulations and data application (Sections 3.6 and 3.7), the grid that is used has
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a point at every hundredth, i.e.,  = 0, 0.01, 0.02, ..., 1. A candidate value of  is
excluded from the confidence set if and only if the hypothesis test for  rejects. If the
confidence set is not an interval, we form a confidence interval using the smallest and
largest points of the set. We present our hypothesis test in Section 3.5.1 and provide
its implementation in Section 3.5.2. The MATLAB code is also provided with this
paper. The asymptotic properties of the resulting confidence interval are presented
in Section 3.5.3.
3.5.1 Hypothesis Test for Candidate Value of  
Let ⇧ denote the set of all L by L matrices with nonnegative, real-valued entries

























  = ( 01, . . . ,  0L,  11, . . . ,  1L)
t
:
For some ⇡ 2 ⇧, we have
⇡
i,j

































This set is comprised of the pairs of marginal distributions (under treatment and
under control) that are compatible with the restrictions. For example, if there are
no restrictions, then   is the set of all vectors with nonnegative entries such that
the sum of the first L entries equals 1 and the sum of the last L entries equals 1.
If the no harm assumption is made and L = 2, the set   comprises all vectors with
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nonnegative entries that satisfy  12    02 and the constraint in the previous sentence.
Under Assumption 3, the pair of true marginal distributions  ⇤ is in the set  .






=  on the right hand side. The set   is comprised
of the pairs of marginal distributions (under treatment and under control) that are
compatible with both the restrictions R and the fraction who benefit being equal to
 . Note that   and   are sets of vectors and not random. Each of these sets is a
bounded, closed, convex polyhedron.
The null and alternative hypotheses for the candidate value of  are
H0( ) :  
⇤ 2   (3.6)
H
a
( ) :  ⇤ 62   . (3.7)
The null hypothesis means that the pair of marginals  ⇤ (which is a function of P
obs
)
is compatible with both the restrictions R and fraction who benefit being equal to  .




) such that its marginals equal




) equals  .




], while the alternative hypothesis is




]. Intuitively, the null hypothesis means that the candidate
value of  is not ruled out by the marginals  ⇤ and the restrictions R.
Let V = (A, Y ). We use the notation P
obs
X to denote the expectation of X with
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, the distribution on V induced by P0 and Assumptions 5 and 6, as
discussed in Section 3.4.3. Define







1(A = a) {1(Y = j)   
aj
}2 .
The minimizer of P
obs
F ( ,V ) over   2   is unique and equal to  ⇤ defined in (3.3).


















denotes the empirical distribution (that is, P
n




m=1 F ( ,V m)).
Let b  be the vector (b 01, . . . , b 0L, b 11, . . . , b 1L), where c 0i = Pn(A = 0, Y =
i)/P
n
(A = 0) and c 1j = Pn(A = 1, Y = j)/Pn(A = 1) for i, j 2 L. The vec-
tor b  represents the empirical marginal distributions of the potential outcomes under
control and under treatment. Let Discrep be the following function of b  and a generic
















The indicator function notation 1(S) equals 1 if S is true and 0 otherwise.
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Lemma 3 is useful for interpreting the test statistic. The function Discrep( , b ) is
a weighted sum of the squared differences between corresponding elements of the
input   and pair of empirical marginals b . Intuitively, Discrep( , b ) measures the
discrepancy between   and b , with higher values indicating more discrepancy. The
test statistic T
n, 
compares the minimum discrepancy from the empirical marginals
b  attained by   2   versus that attained by   2  .
We will reject the null hypothesis that  ⇤ 2   for large values of T
n, 
, as described
below. This involves computing the asymptotic distribution of the statistic under the
null hypothesis, and rejecting if T
n, 
exceeds the 0.95 quantile of this distribution.
Let W = (W01, . . . ,W0L,W11, . . . ,W1L)t 2 R2L be a random (column) vector with
W
aj
= 2 ⇥ 1(A = a)
 
1(Y = j)   ⇤
aj
 
. Let Z = (Z01, . . . , Z0L, Z11, . . . , Z1L)t 2 R2L
be a random (column) vector having a multivariate normal distribution with mean
vector 0 and covariance matrix ⌃ = P0WW t. Define C( ⇤) and C ( ⇤) as
C( ⇤) = {r(     ⇤) :   2  , r 2 R+}, C ( ⇤) = {r(     ⇤) :   2   , r 2 R+},
where R+ is the set of nonnegative real numbers.
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Theorem 4 Under the null hypothesis  ⇤ 2   , T
n, 







(htZ + hth/2)  min
h2C( ⇤)
(htZ + hth/2). (3.10)
Proof We use the general argument in Section 5.1.3 of Shapiro et al. (2014), ex-
cept tailored to our specific problem. The proof here is self-contained. The null hy-
pothesis  ⇤ 2   implies that the minimizer  ⇤ of min
 2  P0F ( , V ) is unique and
satisfies  ⇤
aj
= P0(Y = j|A = a) for each a 2 {0, 1}, j 2 {1, . . . , L}. This implies





F ( ⇤, V ) rP0F ( ⇤, V )}, where the gradient is with respect
to  ⇤. It follows that Z
n












for each a 2 {0, 1}, j 2 {1, . . . , L}. By the multivariate central limit theorem, Z
n
converges in distribution to Z defined above. Let D
n
denote the 2L ⇥ 2L diagonal
matrix with first L diagonal elements equal to 2P
n
1(A = 0) and last L diagonal
elements equal to 2P
n
1(A = 1). For simplicity, we assume that ✓ = 1/2, i.e., P
obs
(A =




) converges in distribution to
(Z,D), for D the 2L⇥ 2L identity matrix.
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F ( , V )  P
n















F ( , V )  P
n












( ⇤) = {n1/2(     ⇤) :   2  }, C 
n
( ⇤) = {n1/2(     ⇤) :   2   }.







F ( , V )  P
n























































































































which proves (3.11). The proof of (3.12) is analogous, except replacing   by   and
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( ⇤) by C 
n
( ⇤).


















( ⇤) " C( ⇤), C 
n




) converges in distribution to
(Z,D), it follows from the continuous mapping theorem that T
n
converges in distri-
bution to T . ⇤











































( ⇤) = {n1/2(     ⇤) :   2  }, C 
n
( ⇤) = {n1/2(     ⇤) :   2   }.
The test statistic T
n, 
is the difference between the left sides of (3.14) and (3.15).
The limit distribution T
 







, and C 
n
replaced with their limits. Their limits are the identity matrix,
Z, C, and C , respectively. Under the alternative hypothesis, the test statistic T
n, 
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does not converge to T
 
, since C 
n
( ⇤) does not converge to C ( ⇤) in this case.




Proof Assume the alternative hypothesis H
a
































































p! ( ⇤, ✓) ,
by the Weak Law of Large Numbers, Slutsky’s lemma, and Theorem 2.7(vi) in van der
Vaart (2000).
For any given n 2 N, we have
P (T
n, 














































Thus, we have P (T
n, 
> M) = P (d
n, 
> M/n). By Lemma 4, Lemma 5, and the




























( , ⇤). If   =  ⇤, Discrep
✓




for all (a, j)
pairs. If   6=  ⇤, we have Discrep
✓




for some (a, j) pair and
0 < ✓ < 1. Since  ⇤ 2  , we have that b = 0. We have c > 0 since  ⇤ /2   and   
is compact, which is proved in Lemma 4. By Slutsky’s lemma, the random variable
d
n, 
converges in probability to positive number c. Let ✏ = c/100. Since the sequence
M/n converges to 0 as n ! 1, we have for sufficiently large n,
P (d
n, 
  c  ✏)  P (d
n, 
> M/n)  1.
Because d
n, 
converges in probability to a, the probability on the left converges to 1.
By the Squeeze Theorem, P (d
n, 
> M/n) = P (T
n, 
> M) converges to 1. ⇤
Lemma 4 The sets   and   ,  2 [0, 1], are compact.
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j=1 ⇡i,j = 1
⇡
i,j


































































































j=1 ⇡i,j = 1
⇡
i,j
































































































j=1 ⇡i,j = 1
⇡
i,j
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Choose any vector ⇡ 2 ⇧ . By the definition of ⇧ , the components of ⇡ satisfy
0  ⇡
i,j
 1 for all i, j. Thus, we have
||⇡|| =
q
⇡21,1 + · · ·+ ⇡21,L + ⇡22,1 + · · ·+ ⇡22,L + · · ·+ ⇡2L,1 + · · ·+ ⇡2L,L  L.
It follows that the set ⇧ is bounded. Also, the set ⇧ is closed since it is a polyhedron.
Since ⇧ is closed and bounded, it is compact. Define the mapping F : ⇧ ! R2L,
where














for all j 2 L.
The mapping F is continuous by Proposition 11.1, Theorem 11.2, and Theorem 11.4
in Fitzpatrick (1996). Let F (⇧ ) denote the image of F : ⇧ ! R2L, i.e.,
F (⇧ ) = { |  = F (⇡) for some point ⇡ 2 ⇧ }.
By Theorem 11.12 in Fitzpatrick (1996), F (⇧ ) is compact. Since   = F (⇧ ), the
set   is compact. ⇤
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Lemma 5 The functions g : (0, 1)⇥ R2L ! R and g
 
: (0, 1)⇥ R2L ! R, defined as













are continuous at (✓,  ⇤).
Proof We prove that g
 
is continuous at (✓,  ⇤). The proof for g is analogous. Con-








) 2 (0, 1)⇥R2L for







) converges to g
 
(✓,  ⇤).
Define the mappings f : R2L ! R and f
n
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( )  f( ). Then we have
 
n




























( 1j    ⇤1j)( ⇤1j   e n,1j).




) converges to (✓,  ⇤), there exists
a positive integer N
↵













( ⇤1j   e n,1j)2 < ↵2.
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| 1j    ⇤1j|| ⇤1j   e n,1j|











































































These mappings are continuous. For any given j 2 {1, 2, 3, 4}, by the Extreme Value
Theorem, the function h
j
:  






) for some  
j






). Let M = max{M
j
: j 2 {1, 2, 3, 4}}.
96
CHAPTER 3. CONFIDENCE INTERVAL FOR THE FRACTION WHO
BENEFIT





( )| < (1  ✓)↵2 + ✓↵2 + ↵M + ↵M + 2(1  ✓)↵M + 2✓↵M = ↵2 + 4↵M.







( )| < ↵2 + 4↵M.
Since the choice of ↵ was arbitrary, we have that sup
 2  | n( )| ! 0.














































































































































































The second inequality holds because | sup
 2   n( )|  sup 2  | n( )| and because
| inf
 2   n( )| = |   sup



















 2  | n( )| ! 0, we have by the Squeeze Theorem that |g (e✓n, e n) g (✓,  ⇤)| !










Intuitively, Theorem 5 is that the test statistic goes to infinity under the alternative
hypothesis. Since the test statistic converges to a distribution (which we can simulate)
under the null hypothesis but to infinity under the alternative hypothesis, our test
can differentiate between the null and alternative hypotheses, as the sample size goes
to infinity.
For any given  , let t0.95
 
denote the 0.95 quantile of T
 
. Reject the null hypothesis




+ ✏, where ✏ = 10 10. The tiny perturbation ✏ is
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required for the proof of pointwise consistency in Section 3.5.3. Let CS
n
be the 95%
confidence set constructed by inverting our hypothesis test, i.e.,
CS
n





3.5.2 Using Quadratic Programming to Implement
the Hypothesis Test




. The test statistic T
n, 
can
be computed from its form in (3.8) or (3.9). We present how to use (3.8). This
requires solving two problems: inf 2  PnF ( ,V ) and inf 2  PnF ( ,V ). We show
that each is the minimization of a quadratic function subject to a finite number of
linear equality and inequality constraints. This is known as a quadratic program.
Quadratic programs can be solved efficiently using existing softwares, such as MAT-
LAB or CPLEX.
Consider the problem inf 2  PnF ( ,V ). Define the following as the unknown
variables: {⇡
i,j
: i, j 2 L}, { 0i : i 2 L}, { 1j : j 2 L}. Let H t denote the vector
including all of these variables. The function to be minimized, P
n
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Each term of the form P
n
(event) is a constant because it can be directly computed
from the randomized trial. Note that (3.23) is a quadratic function of the variables
H
t
. In the problem inf 2  PnF ( ,V ), the function (3.23) is minimized under the
constraint   2  . By (3.17),   2   means that: ⇡
i,j








= 0 if g(i, j) = 0,  0i =
P
L
j=1 ⇡i,j for all i 2 L,  1j =
P
L
i=1 ⇡i,j for all j 2 L.
These are linear equality and inequality constraints on the variables H
t
. Therefore,
one can solve inf 2  PnF ( ,V ) by finding the minimum of (3.23) under the above
constraints, using quadratic programming.
The other problem required to compute T
n, 
is inf 2  PnF ( ,V ). Its corre-
sponding quadratic program is the same as that for inf 2  PnF ( ,V ), except with






We use simulation to estimate T
 
, which is the limiting distribution of T
n, 
un-
der the null hypothesis. Each draw from T
 
is computed as follows. Let b R denote
the minimizer over   2   of P
n
F ( ,V ), previously solved to get the test statistic
T
n, 
. The minimizer may not be unique. We simply let b R be the minimizer that
is returned by “quadprog” in MATLAB. Generate a random draw of Z. This re-
quires first estimating ⌃ by replacing  ⇤ by b R and P0 by Pn in the definition of
⌃. Next, solve the two quadratic programs in (3.10). To solve the second quadratic
program minh2C( ⇤)(htZ + hth/2), define the following variables: {⇡ij : i, j 2 L},
h = (h01, . . . , h0L, h11, . . . , h1L)t,   = ( 01, . . . ,  0L,  11, . . . ,  1L)t. Let H denote the
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g(i, j) = 0,  0j =
P
L
i=1 ⇡ij,  1j =
P
L






b R (note, this is a vector
of equalities). Define the quadratic program to be minhtZ + hth/2, over the vari-
ables H and under the above linear constraints. To solve the first quadratic program
minh2C ( ⇤)(h











We take 1000 draws and compute their 0.95 quantile. Denote this quantile as bt0.95
 
.
The hat symbol is due to the finite number of draws and because we used an estimate




+ ✏, where ✏ = 10 10. The




















3.5.3 Properties of Confidence Set and Correspond-
ing Confidence Interval
Theorem 4 implies the following:
Theorem 6 The confidence set CS
n
is pointwise consistent at level 0.95.
Proof Consider an arbitrary data generating distribution P
obs
on (A, Y ). Suppose
the underlying distribution P0 on (YC , YT ) satisfies Assumption 3. Choose any  that
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is consistent with the marginal distributions and restrictions, i.e.,  ⇤ 2   . Then for








































where the second inequality follows from Theorem 4 and the Portmanteau Lemma
(van der Vaart, 2000). ⇤
Theorem 5 implies the following:




Proof Consider an arbitrary data generating distribution P
obs
on (A, Y ). Suppose the
underlying distribution P0 satisfies Assumption 3. Consider any  such that  ⇤ 62   .















+ ✏) = 1.
⇤
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The confidence set CS
n
generated through test inversion is not guaranteed to be an
interval. A confidence interval, denoted as CI
n
, is constructed by taking the minimum








]. From pointwise consistency
of the confidence set CS
n
, the confidence interval CI
n
is also pointwise consistent.















To compute it efficiently, we implement the hypothesis test for  = 0 and for succes-
sively larger  only until failing to reject, in order to obtain the left endpoint of cCI
n
.
To obtain the right endpoint, we implement the hypothesis test for  = 1 and for
successively smaller  until failing to reject. This reduces computation time because
the hypothesis test does not need to be done for every candidate value of  in the
grid on [0, 1]. Wider intervals will take less time to run.
3.6 Simulation Studies
We use simulation to assess cCI
n
at sample sizes n ranging from 200 to 2000. We
compare it to the m-out-of-n bootstrap, with respect to coverage probability and
average width. Let A and B denote the left and right endpoints of the confidence
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interval constructed using the m-out-of-n bootstrap. To compute the value A, 10,000
bootstrap data sets are generated, each by sampling m  n participants with re-
placement from the trial data set. Using each bootstrap data set, the lower and








proposed in Huang et al. (2017). These estimators were those defined in the previous
chapter. For their intuition and the proof of consistency, refer to Huang et al. (2017).
The value A is taken to be the 0.025 quantile of the 10,000 lower bound estimates.
The value B is the 0.975 quantile of the 10,000 upper bound estimates. The rationale
behind the choice of A and B is
P
obs
(A   0  B)   Pobs(A   R
l












(A >  R
l









(B <  R
u
)
  1  0.025  0.025
= 0.95.
As a sensitivity analysis, we vary m between m = n, 0.9n, 0.75n, 0.5n, and 0.25n.
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A 2 0.5 0.5 0.5 0.5 no restrictions (0,0.5)
B 2 0.5 0.5 0.5 0.5 no harm (0,0)
C 2 0.5 0.5 0.25 0.75 no restrictions (0.25, 0.5)
D 6 empirical marginals in MISTIE II no restrictions (0.82,0.96)
3.6.1 Setup
We compare our method to the m-out-of-n bootstrap in four settings. The set-
tings, labeled A-D, are outlined in Table 3.1. Each setting is a unique choice of the
number of levels L, the marginal distributions  ⇤, the restrictions R, and the true




). For each setting, we conduct a simulation study at each
of the following sample sizes: n = 200, 500, 1000, and 2000. For Settings A-C, each
simulation study includes 5000 simulations. For Setting D, each study includes 1000
simulations since the six-level ordinal outcome results in longer running times. The
randomization probability ✓ is set to 0.5 in all simulations. The steps to run a single
simulation are as follows:
1. We generate a data set consisting of the treatment assignments and observed




) with m = 1, ..., n. Each participant is
randomly assigned to treatment or control using the randomization probability
✓ = 0.5. Her/his observed outcome is a random draw from either  ⇤0· or  ⇤1·,
depending on the assigned treatment.
2. A 95% CI for the fraction who benefit is computed using the method we pro-
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posed in Section 3.5.
3. A 95% CI for the fraction who benefit is computed using the m-out-of-n boot-
strap, as described at the beginning of Section 3.6.
In each simulation study, we plot the coverage probability of each method as a map-
ping from [0, 1] to R. For any given  2 [0, 1], the coverage probability of  equals
the proportion of the confidence intervals that contain  . In addition, we compute
the average width for each method.
3.6.2 Results
We present the coverage probabilities at n = 500 for Settings A and B in Figures
3.1 and 3.2, respectively. In each figure, we shade the region from  =  R
l
to  =  R
u




) = (0, 0), so the grey region is the thin line
at  = 0. In general, under Assumption 3, the fraction who benefit  0 must be in
the grey region and could be anywhere in this region. For  in the grey region, the
probability that the confidence interval contains  should be   0.95.
In Figures 3.1 and 3.2, our method has coverage probabilities   0.95 for all  
in the grey region. Moreover, our method achieves this in all four settings and at
all sample sizes n = 200, 500, 1000, 2000. In contrast, the m-out-of-n bootstrap can
have coverage probability < 0.95 in the grey region. This occurs in Setting A for the
choices m = n, m = 0.9n and m = 0.75n. For instance, the coverage probability of
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 = 0.5, which lies in the grey region, is 0.95 for our method but 0.89 for m-out-of-n
bootstrap (m = n). In contrast, for Settings B-D, the choice m = n yields at least
the nominal coverage and the smallest average width among the choices of m. This
reflects the challenge of choosing m.
In Setting B (Figure 3.2), the set of  for which the null hypothesis  ⇤ 2   is
true is the single point 0 (under the no harm assumption). An impressive result is
that, using our method, the confidence interval is [0, 0] in 50% of the simulations. In
other words, our method gives the best possible confidence interval 50% of the time,
up to the precision of 0.01. The first point in the grid that should be excluded is
 = 0.01. Our method excludes  = 0.01 53% percent of the time. On the other
hand, the m-out-of-n bootstrap excludes  = 0.01 only 6% of the time at best (with
m = n). Our methods’s ability to exclude  outside of the grey region translates to
large improvements in average width.
Our method can have substantially shorter average width than the competitor.
We observe this in Settings B and C. In Setting B, the reduction in average width of
our method (compared to the m-out-of-n bootstrap) ranges from 37-69% at n = 200,
40-70% at n = 500, 41-71% at n = 1000, and 43-71% at n = 2000. (The ranges are
due to trying different options for the choice of m.) In Setting C, the reduction in
average width of our method ranges from 6-33% at n = 200, 7-32% at n = 500, 6-28%
at n = 1000, and 6-23% at n = 2000.
In Settings A and D, the m-out-of-n bootstrap sometimes has narrower average
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Figure 3.1: Coverage probabilities in Setting A at n = 500. The grey region spans





A. To achieve good coverage under Assumption 3, coverage probabilities should be
  0.95 for all  in the grey region. For legibility of the plot, the curves for m = 0.9n
and m = 0.75n are not shown. They lie between the curves for m = n and m = 0.5n,
but closely resemble the curve for m = n.
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Figure 3.2: Coverage probabilities in Setting B at n = 500. The grey region is the





zero. To achieve good coverage under Assumption 3, coverage probabilities should be
  0.95 at  = 0. For legibility of the plot, the curves for m = 0.9n and m = 0.75n
are not shown. They lie between the curves for m = n and m = 0.5n, but closely
resemble the curve for m = n.
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width than our method. In Setting A, this occurs only when the m-out-of-n bootstrap
undercovers, i.e., has coverage probability < 0.95 in the grey region. In Setting
D, the m-out-of-n bootstrap achieves narrower average width at n = 200, with an
improvement ranging from 2-14%. At n = 500, the m-out-of-n bootstrap offers an
improvement of 2% when m = n. However, our method has narrower average width
at the higher sample sizes, with reductions in average width ranging from 3-23% at
n = 1000 and 6-22% at n = 2000.
Our method and the m-out-of-n bootstrap can have poor coverage if Assumption
3 is violated. Consider Setting B and suppose that the no harm assumption does
not hold. Then the true fraction who benefit could be larger than zero, but both
our method and the m-out-of-n bootstrap have coverage probabilities below 0.95 for
candidate values of  > 0 (Figure 3.2). To avoid violating Assumption 3, restrictions
should either be based on subject matter knowledge or no restrictions should be made.
3.7 Application to the CLEAR III trial
3.7.1 Analysis Procedure
We apply our method to the CLEAR III (Clot Lysis: Evaluating Accelerated Res-
olution of Intraventricular Haemorrhage III) randomized trial (Hanley et al., 2017).
This was a Phase III trial from 2009-2016 about intraventricular haemorrhage (IVH),
which is bleeding into the ventricles of the brain, due to a stroke. CLEAR III tested
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whether using the drug alteplase (treatment) to remove the blood clot from the ven-
tricle results in a better functional outcome than using saline (control). The trial
included 500 participants, with 249 assigned to alteplase and 251 to saline. The pri-
mary outcome was the modified Rankin scale (mRS) score at 180 days post-stroke.
The mRS score is an ordinal rating of functional outcome with seven levels. The
levels are defined as follows (this list is quoted directly from Cheng et al. (2014)):
0. no symptoms at all
1. no significant disability: despite symptoms, able to perform all usual duties and
activities
2. slight disability: unable to perform all previous activities but able to look after
own affairs without assistance
3. moderate disability: requiring some help but able to walk without assistance
4. moderately severe disability: unable to walk without assistance and unable to
attend to own bodily needs without assistance
5. severe disability: bedridden, incontinent, and requiring constant nursing care
and attention
6. death.
Based on CLEAR III, the proportion of patients with 180-day mRS  3 was estimated
as 0.48 under alteplase and 0.45 under saline (95% CI for difference in proportions:
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[-0.04, 0.12]).
We consider the primary outcome 180-day mRS, as well as the outcomes 30-day
mRS, 30-day mortality, and 180-day mortality. For the mRS outcomes, we utilize the
full ordinal scale. A separate analysis is performed for each outcome. First, a 95% CI
for the fraction of patients who benefit from alteplase (relative to saline) is computed
using the method proposed in Section 3.5. Participants whose outcome is missing
are excluded. Out of 500 participants, the number of participants who are excluded
is 6 for 30-day mRS, 9 for 180-day mRS, 0 for 30-day mortality, and 5 for 180-day
mortality. Second, we attempt to answer the question of who benefits from alteplase
compared to saline. An existing hypothesis was that patients with large baseline IVH
volumes are more likely to benefit than patients with small baseline IVH volumes.
We define 17.5 mL as the threshold between “small” and “large”, per the suggestion of
neurologist Daniel Hanley. By this definition, 188 of the 500 participants have small
baseline volumes and 312 participants have large baseline volumes. We compute a
95% CI for the fraction of patients with a small baseline IVH volume who benefit
from alteplase compared to saline. This is done by applying our method using solely
the participants with baseline IVH clot volume  17.5 mL. The participants whose
outcome is missing are excluded. Analogously, we compute a separate 95% CI for
patients with a large baseline IVH volume.
All of the CI’s are constructed without using any restrictions (g = 1), so Assump-
tion 3 is met. In CLEAR III, simple randomization with ✓ = 0.5 was implemented
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for the first 100 participants. After this point, a covariate adaptive method was used
to achieve balance between the alteplase and saline arms on two pre-selected baseline
variables. Our method is currently designed for trials using simple randomization.
For the purpose of demonstrating our method, we assume that simple randomization
was performed throughout CLEAR III with ✓ = 0.5. As future work, we will extend
our method to handle more randomization schemes.
3.7.2 Results
The 95% CI’s are presented in Table 3.2. For every CI, we specify the outcome of
interest and whether the CI is for all patients, only those with baseline clot volume
 17.5 mL, or only those with baseline clot volume > 17.5 mL. The corresponding
sample sizes are presented in Table 3.3. For every pairing of outcome with patient
group, we present the sample sizes in the format, total (saline, alteplase).
Table 3.2: 95% CI’s for the Fraction who Benefit from Alteplase Compared to Saline.
All patients  17.5 mL only > 17.5 mL only
30-day mRS [0.00,0.64] [0.00,0.79] [0.00,0.61]
180-day mRS [0.03,0.86] [0.00,0.92] [0.01,0.83]
30-day mortality [0.01,0.18] [0.03,0.13] [0.00,0.23]
180-day mortality [0.05,0.34] [0.02,0.23] [0.04,0.44]
We discuss the results for 30-day mortality. As shown in Table 3.2, the 95% CI for
this outcome is [0.01, 0.18] for all patients. In words, we are 95% confident that the
fraction of patients who benefit with respect to 30-day mortality (i.e., the proportion
who would be alive under alteplase but dead under saline, at 30 days) is between
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Table 3.3: Sample Sizes for 95% CI’s in Table 3.2.
All patients  17.5 mL only > 17.5 mL only
30-day mRS 494 (249,245) 186 (95,91) 308 (154,154)
180-day mRS 491 (245,246) 185 (93,92) 306 (152,154)
30-day mortality 500 (251,249) 188 (95, 93) 312 (156,156)
180-day mortality 495 (247,248) 187 (94,93) 308 (153,155)
0.01 and 0.18. Our result contributes new knowledge that was not provided by the
difference in proportions ATE. The proportion dead at 30 days was estimated to be
0.06 higher under saline compared to alteplase (95% CI: [-0.00,0.11]). The difference
in proportions is a lower bound on the fraction who benefit. Using the 95% CI for
the difference in proportions, we could only infer that the fraction who benefit is 0 or
above. As shown in Table 3.2, the 95% CI for the fraction who benefit is [0.03, 0.13]
for those with baseline clot volume  17.5 mL, and [0, 0.23] for those with baseline
clot volume > 17.5 mL. The first result suggests that there is a small proportion who
benefit among those with  17.5 mL. However, it is inconclusive whether those with
> 17.5 mL are more likely to benefit than those with  17.5 mL since the 95% CI
for > 17.5 mL is wider in both directions. Further work is required to identify the
subgroup that benefits with respect to 30-day mortality. One could develop a scalar
score using multiple baseline covariates, and stratify patients using the score rather
than a single baseline covariate.
As shown in Table 3.2, the 95% CI’s for the mortality outcomes are narrow, while
those for the mRS outcomes are very wide. The 95% CI for 180-day mRS and all
patients is [0.03, 0.86]. The finite sample size of n = 491 (Table 3.3) contributes to
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the CI width. However, we believe the main factor behind the wide width is that
the true lower and upper bound parameters span a wide range. In other words, the
marginal distributions of the potential outcomes alone are not very informative about
the fraction who benefit. Support restrictions can potentially reduce the width of the
bounds. In this setting, current subject matter knowledge does not imply any support
restrictions.
3.8 Discussion
We have developed a new method for constructing a 95% confidence interval for
the fraction who benefit. It offers the user flexibility to define support restrictions
based on subject matter knowledge or to make no assumptions at all on the joint
distribution of the potential outcomes. Our confidence interval is proved to be point-
wise consistent. In simulation tests, it had empirical coverage of at least 95% when
the sample size was varied from 200 to 2000. The method is computationally efficient
because it uses quadratic programming to compute the test statistic and the distri-
bution of the test statistic under the null hypothesis. It also avoids having to choose
m.
Our simulations and CLEAR III application show that the confidence interval
constructed using the method can be narrow and informative. However, we also en-
countered cases in which the confidence intervals are wide, likely due to the true lower
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and upper bound parameters being far apart. Our confidence interval is designed so
that for any given value between the lower and upper bounds, the coverage of the value
is at least 0.95. Consequently, if the bounds are far apart, the confidence intervals
will tend to be wide even for extremely large sample sizes. Huang et al. (2017) found
that incorporating a baseline variable can substantially narrow the bounds, without
requiring assumptions. As future work, we will incorporate a baseline variable into
our method. Also, we will provide guidance on how to select a baseline variable that




I have developed a method to estimate lower and upper bounds on the fraction
who benefit. I prove that the estimator is consistent. It is also computationally
efficient because it uses linear programming. In addition, I have developed a method
to construct a confidence interval for the fraction. This confidence interval is pointwise
consistent and can be computed using quadratic programming.
As future work, I will extend these methods to handle the case of missing outcome
data due to loss to follow-up, which is common in real trials. The methods currently
are designed for the case of a simple randomized trial design, i.e., each subject’s treat-
ment assignment is a random draw from the same Bernoulli distribution. I will extend
the methods to more complex randomization schemes. In addition, I will extend the
methods to handle not only randomized trial data, but also observational study data.
This can be useful in applications where randomized trial data is unavailable. An
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extension to observational studies would require some assumptions about how to get
consistent estimates for the marginal distributions of the potential outcomes.
I plan to apply the methods to more randomized trials to determine whether
the results tend to be informative (i.e., the bound estimates and the CI for the
fraction who benefit are narrow). A challenge is addressing the case where the results
are uninformative due to the bound parameters themselves being wide. To address
this challenge, further work should try to incorporate subject matter knowledge that
cannot be expressed in the form of support restrictions. One option is to make
assumptions about the correlation between the potential outcomes under control and
treatment. Other than user-defined assumptions, I prove in Chapter 2 that a baseline
variable can tighten the bound parameters. Currently, the CI method in Chapter 3
only uses treatment assignment and outcome data from a trial. I will extend it to
also incorporate data about a baseline variable. Because many baseline variables can
be collected in a single trial, I will address the question of selecting which baseline
variable to incorporate. The aim is to choose the variable that results in the most




Table 5.1: Estimated Bounds on the Fraction who Benefit, with respect to 30-day
mRS Score.
























Benefit  5 .07 .61 0 .17 .52
 4 .07 .61 0 .17 .52
 3 .07 .61 0 .17 .52
 2 .09 .61 0 .17 .52
 1 .12 .61 0 .22 .52
Harm  5 .07 .61 0 .17 .52
 4 .07 .61 0 .17 .52
 3 .07 .61 0 .17 .52
 2 .07 .59 0 .17 .52
 1 .07 .50 0 .17 .45
No Harm .03 .26 .02 .15 .30




















.04 .41 0 .26 .60 0
.04 .41 0 .26 .60 0
.04 .41 0 .26 .60 0
.04 .41 0 .26 .60 0
.06 .41 0 .33 .60 0
.04 .41 0 .26 .60 0
.04 .41 0 .26 .60 0
.04 .41 0 .26 .60 0
.04 .41 0 .26 .60 0
.04 .26 0 .26 .60 0
0 .26 .06 .26 .33 0
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Table 5.2: Estimated Bounds on the Fraction who Benefit, with respect to 180-day
mRS Score.
























Benefit  5 .10 .73 0 .13 .64
 4 .10 .73 0 .13 .64
 3 .10 .73 0 .14 .64
 2 .12 .73 0 .18 .64
 1 .18 .64 0 .25 .64
Harm  5 .10 .73 0 .13 .64
 4 .10 .73 0 .13 .64
 3 .10 .64 0 .13 .63
 2 .10 .62 0 .13 .63
 1 .10 .42 0 .12 .51
No Harm .10 .18 0 .12 .54




















.01 .59 0 .22 .68 0
.01 .59 0 .22 .68 0
.01 .59 0 .25 .68 0
.01 .59 0 .32 .68 0
.01 .57 0 .44 .69 .02
.01 .59 0 .22 .68 0
.01 .59 0 .22 .68 0
.01 .57 0 .22 .68 0
.01 .57 0 .22 .68 0
.00 .35 .04 .22 .64 0
.00 .52 .08 .22 .55 0
Table 5.3: Estimated Bounds on the Fraction who Benefit, with respect to RICV5.
























Benefit  4 .87 .96 0 .83 .98
 3 .56 1 .18 .58 1
 2 .27 1 .30 .33 1
 1 .18 1 .35 .15 1
Harm  4 .82 .96 0 .83 .96
 3 .82 .96 0 .83 .96
 2 .82 .96 0 .83 .96
 1 .82 .96 0 .83 .96
No Harm .82 .96 0 .83 .96




















.81 .96 0 .86 1 .05
.68 1 .12 .47 1 .23
.49 1 .22 .17 1 .38
.30 1 .31 .00 1 .43
.81 .96 0 .86 .96 0
.81 .96 0 .86 .96 0
.81 .96 0 .86 .96 0
.81 .96 0 .86 .96 0
.81 .96 0 .86 .96 0
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Table 5.4: Estimated Bounds on the Fraction who Benefit, with respect to RICV2.
























Benefit  10 .87 .96 0 .85 .98
 9 .75 1 .10 .76 1
 8 .63 1 .15 .65 1
 7 .52 1 .21 .49 1
 6 .33 1 .29 .35 1
 5 .28 1 .32 .28 1
 4 .25 1 .33 .24 1
 3 .22 1 .34 .17 1
 2 .14 1 .37 .11 1
 1 .06 1 .40 .10 1
Harm  10 .84 .96 0 .87 .96
 9 .84 .96 0 .87 .96
 8 .84 .96 0 .87 .96
 7 .84 .96 0 .87 .96
 6 .84 .96 0 .87 .96
 5 .84 .96 0 .87 .96
 4 .84 .96 0 .87 .96
 3 .84 .96 0 .87 .96
 2 .84 .96 0 .87 .96
 1 .84 .96 0 .87 .96
No Harm .84 .96 0 .87 .96




















.84 .96 0 .86 1 .05
.90 .99 .03 .62 1 .15
.68 1 .12 .62 1 .15
.57 1 .18 .42 1 .25
.52 1 .20 .17 1 .38
.39 1 .25 .17 1 .38
.36 1 .27 .12 1 .40
.30 1 .31 .04 1 .43
.19 1 .35 .04 1 .43
.15 1 .38 .06 1 .43
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
.84 .96 0 .89 .96 0
Table 5.5: Estimated Bounds on the Fraction who Benefit, with respect to RICV1.
























Benefit  2 .87 .96 0 .83 .98
 1 .27 1 .30 .28 1
Harm  2 .82 .96 0 .83 .96
 1 .82 .96 0 .83 .96
No Harm .82 .96 0 .83 .96




















.81 .96 0 .86 1 .05
.38 1 .21 .17 1 .38
.81 .96 0 .86 .96 0
.81 .96 0 .86 .96 0
.81 .96 0 .86 .96 0
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Table 5.6: Estimated Bounds on the Fraction who Benefit, with respect to RICV2.
























Benefit  1 .87 .91 0 .76 .85
Harm  1 .65 .91 0 .64 .83
No Harm .65 .87 0 .64 .81




















.66 .70 0 .86 1 .05
.42 .70 0 .86 .96 0
.42 .66 0 .86 .96 0
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1 nT = 54 , nC = 42 treatment
control
1 2 3 4 5 6 7 8 9 10 11 12
Subpopulation with low baseline clot volume
RICV2
0
1 nT = 26 , nC = 22
1 2 3 4 5 6 7 8 9 10 11 12
Subpopulation with high baseline clot volume
RICV2
0
1 nT = 28 , nC = 20








1 nT = 54 , nC = 42 treatment
control
1 2 3 4
Subpopulation with low baseline clot volume
RICV10
0
1 nT = 26 , nC = 22
1 2 3 4
Subpopulation with high baseline clot volume
RICV10
0
1 nT = 28 , nC = 20








1 nT = 54 , nC = 42 treatment
control
1 2 3
Subpopulation with low baseline clot volume
RICV20
0
1 nT = 26 , nC = 22
1 2 3
Subpopulation with high baseline clot volume
RICV20
0
1 nT = 28 , nC = 20
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